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 Rapidly evolving technologies such as chip arrays and next-generation sequencing are 
uncovering human genetic variants at an unprecedented pace.  Unfortunately, this ever growing 
collection of gene sequence variation has limited clinical utility without clear association to 
disease outcomes.  As electronic medical records begin to incorporate genetic information, gene 
variant classification and accurate interpretation of gene test results plays a critical role in 
customizing patient therapy.  To verify the functional impact of a given gene variant, laboratories 
rely on confirming evidence such as previous literature reports, patient history and disease 
segregation in a family. By definition variants of uncertain significance (VUS) lack this supporting 
evidence and in such cases, computational tools are often used to evaluate the predicted 
functional impact of a gene mutation.  
 This study evaluates leveraging high quality genotype-phenotype disease variant data 
from 20 genes and 3986 variants, to develop gene-specific predictors utilizing a combination of 
changes in primary amino acid sequence, amino acid properties as descriptors of mutation 
severity and Naïve Bayes classification. A Primary Sequence Amino Acid Properties (PSAAP) 
prediction algorithm was then combined with well established predictors in a weighted Consensus 
sum in context of gene-specific reference intervals for known phenotypes.  PSAAP and 
Consensus were also used to evaluate known variants of uncertain significance in the RET proto-
oncogene as a model gene.   
The PSAAP algorithm was successfully extended to many genes and diseases. Gene-
specific algorithms typically outperform generalized prediction tools.  Characteristic mutation 
properties of a given gene and disease may be lost when diluted into genomewide data sets.  
A reliable computational phenotype classification framework with quantitative metrics and 
disease specific reference ranges allows objective evaluation of novel or uncertain gene variants 
and augments decision making when confirming clinical information is limited.    
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Medical genetics involves diagnosis, management, and determining risk of hereditary 
disorders.[1, 2]  The genotype-phenotype correlation of gene variants in disease is a major 
component of medical genetics.  In monogenic diseases, gene mutations are typically curated as 
either pathogenic or benign. However, many gene variants must be classified as “unknown” or 
“uncertain” significance because they have not been clearly associated with a clinical 
phenotype.[3]  Accurate interpretation of gene testing is a key component in customizing patient 
therapy.   
The investment of time and labor to validate disease association of a variant of uncertain 
significance (VUS) within the coding portion of a gene can be daunting and cost prohibitive.[4, 5]  
This is due in part to the nature of rare mutations, the lack of available functional assays or lack of 
power from a limited number of family studies, as well as the interactions between clinicians and 
laboratory geneticists needed to characterize novel gene variants.[6, 7]  To help bridge this 
genotype-phenotype gap, the use of machine learning classification algorithms to narrow the 
uncertain “grey area” between pathogenic and benign sequence variants warrants careful 
evaluation.[8-11]  Reliable machine-based classification may augment costly patient recruitment, 
family histories, and biochemical confirmation of a gene variant with no associated disease 
correlation.[12-14] 
Machine learning is common to many industries with well known applications including 
speech recognition, internet search engines and detecting credit card fraud.[15, 16]  In medicine 
and biology, computers often assist in tasks such as natural language processing, medical 
records and DNA sequence alignment.[17, 18]   
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Rapidly evolving technologies such as SNP chip genomewide association studies and 
next-generation sequencing has lowered the cost and increased the speed of genomic analysis 
yielding much larger data sets.  Currently, gene variants are being discovered at an 
unprecedented pace. One recent report found an average of 3 million variants per personal 
genome.[19]  Unfortunately, an ever-widening gap exists between this fast growing collection of 
genetic variation and practical clinical implementation due to a lack of understanding of the 
phenotypic consequences (if any) of any given variant.[20, 21]   
Early efforts to develop clinical laboratory systems date back nearly 50 years, with 
electronic processing and reporting of laboratory test results.[22, 23]  Additional efforts continued 
to improve and refine computer information systems used in laboratory settings and to enhance 
patient care.[24, 25]  As genetic information began to influence patient care, laboratory 
information systems again required adjustments.[26, 27]  Currently, the vast amount of genomic 
data on the horizon for medical records and patient treatment highlights increasing opportunities 
for genomic data decision support in the laboratory setting.  Furthermore, where traditional 
decision support augments choosing the correct decision or task, moving toward a more 
complete environment of gene variant information that supports cognition in context of problem 
and workflow, may enhance accurate gene test interpretation and necessary laboratory 
recommendations - prior to a clinician acting in appropriate patient care.[28-30]  
Recent endeavors such as the NCBI Genetic Testing Registry, 1000 Genomes and the 
Human Variome Project highlight this growing interest in gene variant annotation and clinical 
interpretation in human disease.[31-33] Over the past several decades, literature reports of 
genotype-to-phenotype (G2P) correlation have grown exponentially.  Figure 1.1 shows nearly 
17,000 such studies reported in PubMed in the last decade alone. 
A given gene variant may be commonly referred to as a single nucleotide polymorphism 
(SNP) or single nucleotide variant (SNV).  More specifically, a nonsynonymous SNP (nsSNP) 















Figure 1.1 Growing wave of scientific literature dealing with gene variant information 
(genotype) and disease association (phenotype), from PubMed (March 2011) with search 
terms “genotype phenotype” and filtered to “human” and “English” only. 
 
The fact that certain nsSNPs are causative of disease is well known.[34]  Thus, 
investigating SNP functional effect has been ongoing for many years.[35-37] Due to the cost, 
labor and expertise required for wet-bench molecular evaluation, much of this effort has been 
done using computational tools. These prediction tools often focus on SNPs in protein coding 
regions that change one amino acid for another.[36]  The severity of a given amino acid 
sequence change may range from mild to severe, and has been reported to impact various 
medical areas including genetic disease susceptibility such as sickle cell anemia, common 
disease risks like Alzheimer’s or drug sensitivities as seen in warfarin treatment.[38]  It is not 
surprising then, that physical and chemical properties of amino acids have been used historically 
as a proxy to assess the functional impact of these substitution mutations.[35]    
 Early efforts in predicting amino acid substitution effects were based on metrics of 
estimating expected evolutionary distance between each possible amino acid pair. One of the first 
amino acid substitution matrices, Point Accepted Mutation (PAM), approximated the evolutionary 
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distance and frequency of amino acids for equivalent protein positions in closely related 
species.[39, 40]  Later, Blocks of Amino Acid Substitution Matrix (BLOSUM) included more 
distantly related species, but only considered highly conserved protein regions.[41]  Interestingly, 
both approaches used raw mutation rates to compute a score for each amino acid substitution 
and calculating likelihood that the mutation was caused by an evolutionary change (over time), 
rather than by sheer chance.  The assumption was that substitutions more consistent with 
evolutionary trends conserved across many species are less likely to disrupt protein function.  
Conversely, substitutions not consistent with evolution (nonconserved substitutions) were more 
likely associated with disease.  
 Alternative approaches utilizing amino acid properties have considered how 
physiochemical properties differ with changes in volume, hydrophobicity, net charge, packing 
density and solvent accessibility all shown to correlate with predicted functional impact of SNPs. 
[37]  A representative method, the Grantham distance, combines both biophysical properties and 
evolutionary distance where the significance of the amino acid substitution was quantified in a 3D 
space as weighted Euclidean distance of side chain composition, polarity and volume as 
coordinates.[42]  Weights were modeled to estimated amino acid substitution mutation rates.[43] 
Importantly, while PAM and BLOSUM matrix likelihood scores or biophysical properties changes 
seen as large Grantham distances may be able to predict effects across large populations of 
SNPs, these computational metrics were not sufficiently accurate for predictions of specific and 
individual SNPs.[44, 45]   One recent report used a combined conservation score of 16 amino 
acid properties as descriptors of mutation to improve the prediction of T4 lysozyme missense 
mutations.[46] 
Subsequent efforts then focused on the fact that the importance of the evolutionary 
distance separating a pair of amino acids depends on the position where an amino acid 
substitution occurs.[44]  More specifically, amino acid distribution at equivalent positions in a 
protein family is functionally or structurally important, where these positions may not tolerate a 
variety of amino acid changes. These equivalent positions were found by constructing an 
alignment from multiple related protein sequences.  Thus, amino acid residues in highly 
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conserved alignment regions were assumed to be under some purifying evolutionary selection 
and important for normal protein function. Algorithms were designed to quantify this conserved 
evolutionary selection in protein activity, such as calculating the frequency of the most common 
amino acid in an alignment column. For example, Shannon entropy computes the distribution of 
all amino acids at a specific aligned position.[47] This idea was further improved by using relative 
entropy to augment comparing Shannon entropy of a conserved alignment against the Shannon 
entropy of the amino acid background distribution.  
Several resulting algorithms and prediction scoring included both physicochemical 
properties of amino acid substitution and evolutionary conservation. For example, the Sorting 
Intolerant From Tolerant (SIFT) algorithm computes a weighted frequency average of which 
amino acid residue appears in a multiple alignment position, coupled with an estimate of 
unobserved variant frequencies.[48] The Position-Specific Independent Counts (PSIC) profile 
score considered the difference of likelihood between reference and variant amino acid at a given 
aligned position using a position-specific scoring matrix (PSSM).[49, 50] Another example is 
Align-GVGD (AGVGD), an extension of the original Grantham difference (GD) to multiple 
sequence alignments and true simultaneous multiple comparisons, where the Grantham variation 
(GV) is computed by replacing each value-pair of a given amino acid residue component for 
composition, polarity and charge with the maximum and minimum value in that alignment 
position.[51]  A final example, the Multivariate Analysis of Protein Polymorphism (MAPP) score 
constructs a statistical summary of an alignment column by use of phylogenetic tree and tree 
topology weighting each sequence by branch length.[52, 53]  
Lastly, it is important to mention algorithms for protein structure–function relationships.  
Where a nsSNP of interest can be mapped onto a known 3D protein structure, it is possible to 
determine several properties useful in predicting functional impact of amino acid substitution. 
Solvent accessibility of an amino acid is one of the strongest predictors of functional impact, 
where substituting various amino acid residues may disrupt the hydrophobic core of a soluble 
protein. Structural modeling of disease proteins can be used to determine whether a nsSNP 
results in backbone strain or leads to overpacking.[54]  Importantly, a large number of X-ray 
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crystal structures have been determined which often include protein interacting partners, and/or 
small molecule, peptide ligands or inhibitors.  The ability to locate a nsSNP on a computational 
protein structure also makes it possible to evaluate whether the amino acid substitution occurs in 
or near a binding or catalytic site or at a domain–domain interface of protein interaction.  One 
popular example of an algorithm taking advantage of structural modeling is Polymorphism 
Phenotyping (PolyPhen).  This is an automated tool for evaluating possible impact of amino acid 
substitution on the structure and function of a human protein that uses a Dictionary of Secondary 
Structure in Proteins (DSSP) to map a given substitution site to known protein 3D structures.[14]  
Although clinicians rely on patient history, family segregation, literature review and 
trusted colleagues to stay informed of the phenotypic consequences of a given gene variant, 
when traditional evidence is lacking, well-established machine learning or computational tools are 
also employed – both for prediction and to assess likelihood.[3, 55-57]  Established methods for 
predicting mutation severity based on amino acid substitution penalties, structural disruption, or 
sequence homology (ortholog conservation) include tools such as PolyPhen [14], SIFT [48], 
MutPred [10] and PMut [58].  Efforts such as dbNFSP have also been reported to archive multiple 
predictors into a single resource.[59]  However, established algorithms will not always complete 
the prediction – due to lack of adequate homolog sequence alignment or availability of a solved 
protein structure.  Furthermore, predictor results are not always in agreement with curated data or 
each other.[60-62]  Thus, there are opportunities to explore the use of other informatics 
approaches to this problem.  
An obvious key to improving prediction algorithms is finding the most authoritative source 
of gene variant data with clear association to disease outcomes.  Optimal training sets can then 
be developed for use in machine learning efforts.  Recent literature indicates that gene test 
reporting of uncertain gene variants range widely.  One laboratory reported that between 30% to 
50% of sequence variants reported for BRCA1 and BRCA2 were reported as variants of uncertain 
significance.[63]  A second laboratory reported test orders for BRCA1 and BRCA2 had an equal 
chance (13%) of receiving an uncertain variant result as seeing a report for a known pathogenic 
gene variant.[64]  More recent data indicate that reports of uncertain gene variants have 
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continued to decline to approximately 5% of BRCA tests performed, thus, highlighting the 
importance of maintaining and updating variant databases.[65]   
Although collections of human genome variation have been underway for years, 
authoritative repositories of gene variants with clear association to disease phenotype are only 
now beginning to emerge.[66-70]  This is in contrast to existing collections of genome-wide 
mutations such as dbSNP[71] or OMIM[72] that are not curated using consistent, systematic or 
transparent methods.  As well-curated locus-specific databases of disease causing gene variants 
become more widely available and relied upon by clinical laboratories, there may be opportunities 
to improve prediction algorithms in a gene-specific manner - without dependence on multiple 
species conservation or solved protein crystal structure.  Examples of this gene-disease specific 
focus using computational prediction have recently been shown for hypertrophic cardiomyopathy 
and in the RET proto-oncogene.[73-75] 
When confirming evidence is obvious lacking, how does the laboratory decide what 
disease classification to report for a gene variant?  The key process is gathering and evaluating 
the strength of evidence for related disease association for a gene variant in question – 
distancing the variant from uncertain significance to a confirmed phenotype.  Figure 1.2 displays 
this concept.  While a conclusive laboratory gene test result will prompt appropriate treatment for 
a patient, an inconclusive gene test interpretation may leave the clinician or patient with 
indecision and/or a frustrating lack of treatment options.   
Guidelines and terminology for improved classification of gene variants have been 
recently proposed.[3, 76]  Clinician frustration and obstacles to wide adoption of proposed 
guidelines may include the lack of a quantitative metric or standardized scale for evaluation of 
novel or uncertain gene variants.   
A closely related challenge is an objective and standardized context or framework to 
make that metric meaningful.  This “strength of evidence framework” becomes especially critical 
for interpretation of uncertain gene variants where there is an obvious lack of existing evidence.  
A reliable computational phenotype classification framework with a quantitative metric for 








Figure 1.2 Gathering strength of evidence for gene variant classification through multiple 
literature reports, functional studies, genetic concordance studies, family history, clinical 




Leveraging authoritative gene-disease collections and amino acid physicochemical 
properties as descriptors of wildtype and mutant, machine learning classification can be used to 
train gene-specific algorithms that outperform generic prediction tools. Integration into a 
standardized framework and quantitative metric for objective evaluation of uncertain gene 
variants may augment laboratory classification of gene test results. 
 
Specific aims 
Laboratory decision support for gene variant classification can be improved by:  
Specific Aim 1. Primary protein sequence and biochemical properties of amino 
acid residues can be used as descriptors of differences between wild type and variant.  
Using the RET proto-oncogene as a model, machine-learning classification algorithms will be 
evaluated for their ability to distinguish benign and pathogenic gene variants as characterized by 
differences in values of physicochemical properties of the amino acid residue present in the wild 
type and mutant.  Representative algorithms will be chosen from different categories of machine 
learning classification techniques, including rules, bayes, regression, nearest neighbor, support 
vector machines and trees. Machine-learning models will then be compared to well-established 
techniques used for mutation severity prediction.   
Specific Aim 2. Machine learning classification can be used to predict 
pathogenicity of uncertain gene variants in authoritative gene-disease collections.  
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Reported gene variants in the RET proto-oncogene have been directly associated with multiple 
endocrine neoplasia type 2 and hereditary medullary thyroid carcinoma, yet some 46 non-
synonymous variants of uncertain significance (VUS) exist in curated archives.  In the absence of 
a reliable method for predicting phenotype outcomes, feature selected amino acid physical and 
chemical properties feeding a Bayes classifier will be used to predict disease association of 
uncertain gene variants into categories of benign and pathogenic.  Algorithm performance and 
VUS predictions will be compared to established phylogenetic based mutation prediction 
algorithms.  Gene-specific prediction will also be extended into 20 gene-disease data sets, 
containing 3,986 well characterized variants. 
Specific Aim 3. A combined score of complementary predictors can be computed 
in a standard framework of gene-specific disease outcomes.  Although proposed guidelines 
have recommended classification terminology and definitions for improving laboratory gene 
variant reporting, a standardized framework does not yet exist for quantitative evaluation of 
disease association for uncertain gene variants in an objective manner.  Gene-specific prediction 
will be trained using clinically curated gene-disease data sets and implemented into a Consensus 
framework.  This prediction model will include a weighted metric of existing and complementary 




As medical records increasingly incorporate genetic test information, improved decision 
support approaches are needed to provide clinicians with the preferred course of treatment.[77]  
Furthermore, for decision support rules to be of value, the clinical relevance of laboratory 
information must be well understood.  Recent attention has focused on providing “on demand” 
gene variant information in medicine.[78] One-click interpretation or additional information 
available through such methods as “info buttons” and graphical summaries may augment clinical 
decision making.[78, 79]  
 Towards this goal, high quality genotype-phenotype disease variant data was leveraged 
to develop a gene-specific predictor utilizing a combination of primary amino acid sequence, 
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amino acid properties as descriptors of mutation severity and Naïve Bayes classification based 
on authoritative training sets. This Primary Sequence Amino Acid Properties (PSAAP) prediction 
algorithm was then used to evaluate known variants of uncertain significance in the RET proto-
oncogene as a model.  Where traditional confirming evidence was lacking, a weighted metric of 
PSAAP with other established and complementary predictors was computed for objective VUS 
evaluation. Finally, the Consensus interpretation framework was implemented using laboratory 
reference intervals of known disease outcomes for scoring uncertain variants to better 
communicate the gathered computational evidence to clinical decision makers. Data and 
methods used for this study were approved by the University of Utah Institutional Review Board 
(IRB #00035757).    
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Although many reported mutations in the RET oncogene have been directly associated 
with hereditary thyroid carcinoma, other mutations are labeled as uncertain gene variants 
because they have not been clearly associated with a clinical phenotype. The process of 
determining the severity of a mutation is costly and time consuming. Informatics tools and 
methods may aid to bridge this genotype-phenotype gap. Towards this goal, machine-learning 
classification algorithms were evaluated for their ability to distinguish benign and pathogenic RET 
gene variants as characterized by differences in values of physicochemical properties of the 
residue present in the wild type and the one in the mutated sequence.  Representative algorithms 
were chosen from different categories of machine learning classification techniques, including 
rules, bayes, regression, nearest neighbor, support vector machines and trees. Machine-learning 
models were then compared to well-established techniques used for mutation severity prediction.  
Machine-learning classification can be used to accurately predict RET mutation status using 
primary sequence information only. Existing algorithms that are based on sequence homology 
(ortholog conservation) or protein structural data are not necessarily superior. 
 
Introduction 
Accurate prediction of the functional severity for uncertain variants and novel mutations 
as relating to disease is of great importance to medicine and biology.  Bridging the genotype-
phenotype gap for uncertain gene variants and novel mutations provides a prime opportunity for 
application of informatics methods.  The process of determining the severity of a mutation is 
costly and time consuming and informatics tools and methods may aid to bridge this genotype-
phenotype gap.  If proven sufficiently reliable, it may ultimately be possible to use these methods 
as diagnostic tools.  At a minimum they can help to prioritize the studies of the mutations more 
likely associated with severe prognosis.   
There are established methods for predicting mutation severity based on substitution 
penalties, structural disruption, or sequence homology (ortholog conservation), such as PolyPhen 
[1], SIFT [2] and MutPred [3].  However, prediction algorithms are not always in agreement with 
curated data or each other [4-6].  Thus, there are opportunities to explore the use of other 
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informatics approaches to this problem. Machine learning methods that can be trained on data 
available in well-curated gene variant collections are promising tools to improve the predictive 
capabilities available to the research community. While many existing models to predict severity 
of mutations are based on sequence similarities based on phylogenetic arguments, this approach 
attempts to use physicochemical properties of amino acids. Numerical values for amino acid 
properties have been previously reported as descriptors for classification[7, 8]. Our assumption is 
that because the physicochemical properties of amino acids define their binding properties, they 
may be better descriptors of the differences between wild type and mutant. 
The RET oncogene is located on chromosome 10q11, with 21 exons coding a full length 
protein of 1,114 amino acids.  Conserved functional domains found within the protein 
(RET_HUMAN, http://www.uniprot.org/uniprot/P07949) include a signal peptide, cadherin repeat 
domains, transmembrane domain, and protein tyrosine kinase [9]. Mutations in the RET 
oncogene (REarranged during Transfection; OMIM# 164761) have been directly associated with 
Multiple Endocrine Neoplasia type 2 (MEN2), a hereditary thyroid carcinoma syndrome [10, 11].  
Although well known mutations often guide patient therapy and surgical options [12], other RET 
sequence mutations vary in functional severity. Some are pathogenic, some are benign, and 
some are of unknown significance. Curated RET oncogene mutations for MEN2 have been 
recently reported, many of which have documented phenotype outcomes [13].  Figure 2.1 
displays reported disease causing variants as associated with different MEN2 phenotypes.   
Table 2.1 summarizes mutation-guided therapy for thyroid cancer where surgical removal 
of thyroid is guided by codon position of the RET mutation. 
 
Table 2.1 RET mutation guided therapy for surgical removal of the thyroid.a  
 
 
RET Codon    Thyroidectomy   Phenotype 
 
883, 918     within first 6 months    MEN 2B 
 
609, 611, 618, 620, 630, or 634  within first 5 years    MEN 2A 
 
768, 790, 804, or 891   within 5 - 10 years  FMTC 
 





Figure 2.1 - RET protein domains.  Schematic view of the RET oncoprotein showing 
conserved domains of signal peptide (SP), cadherin repeat domains (CAD), cysteine rich 
region (CYS), transmembrane domain (TM), and protein tyrosine kinase (Kinase) where 
reported variants associate to three specific disease phenotypes; familial medullary 
thyroid cancer (FMTC), multiple endocrine neoplasia type 2A (MEN2A) and multiple 
endocrine neoplasia type 2B (MEN2B).  
 
Accurately predicting the mutation severity for gene variants in the RET oncogene could 
help clinicians identify patients less likely to respond to standard treatments, assist patients when 
making informed decisions about their care, and aid researchers in understanding mechanisms of 
disease severity. 
Here we examine the hypothesis that novel informatics tools can take advantage of well-
curated gene variant collections, utilizing physicochemical properties of the amino acids in the 
coded proteins to determine mutation severity. This study evaluates the performance of machine-
learning classification algorithms for predicting mutational severity in RET oncogene variants with 
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known genotype-phenotype association when using representative chemical, physical, energetic, 
and conformational  properties of amino acids as descriptors of the mutation.   
 
Methods 
A curated set of non-synonymous RET mutations with known phenotype severity 
(“pathogenic” or “benign”), publicly available at http://www.arup.utah.edu/database/, [13] was 
used to train and test representative machine learning classification algorithms. Archived RET 
gene variants were accessed from this database in January 2010.  Sequence variants were 
verified for their position within the RET gene and named following standard Human Genome 
Organisation (HUGO) nomenclature.  
RET mutations were characterized by the absolute differences between the values of 544 
amino acid properties (AAIndex v9.4) of the residue present in the wild type and the one in the 
mutated sequence [15, 16].   The Correlation-based Feature Subset Selection algorithm [17], 
together with the Best First (greedy hillclimbing) search method, were used to identify the subset 
of properties that best differentiated benign mutations from pathogenic ones, based on the amino 
acid changes in RET.  After feature selection was performed on training sets, selected properties 
specific to each training set (k=3) were carried forward as attributes for classification.  Thus, each 
mutation was described by an array of variables, corresponding to the absolute value of the 
difference between the value of the property in the amino acid present in the wild type and the 
one in the mutant.    
Due to the limited amount of clinically curated variants available publically, cross fold 
validation (k=3) was used to train and test classification of disease phenotype.  The sample set 
(n=104) used 58 pathogenic variants specific to MEN2 phenotype and 46 benign variants.   The 
data set only used nonsynonymous variants where one amino acid was substituted for another.  
Because of the limited sample size, we chose to perform cross validation rather than the ideal 
method of holding data separate for external validation.   
For this study, five different machine-learning classification algorithms were evaluated 
including: ZeroR (zero rules), bayes (NaiveBayes), regression (SimpleLogistic), support vector 
machine (SMO), k nearest neighbor (IBk), and trees (RandomForest).  Machine-learning 
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classification algorithms with their respective default settings as implemented in the Weka 
software package (v3.6) were used in this study [18].   Because “accuracy” is a term often 
plagued with misinterpretation, we choose to evaluate algorithm performance using previously 
reported and less ambiguous values of sensitivity, specificity, and positive predictive value [19].   
Finally, the above classification models were also compared to existing mutation 
prediction algorithms based on sequence homology, amino acid substitution penalties or 
structural disruption using the full set of RET mutations with their curated  outcomes.  The SIFT 
algorithm is available on-line at http://sift.jcvi.org/ and gives outcomes of “tolerated” (meaning 
predicted benign) and “affects protein function” (meaning predicted pathogenic). PolyPhen was 
accessed at http://genetics.bwh.harvard.edu/pph and has outcomes of “benign” and “probably 
damaging” (meaning predicted pathogenic).  MutPred is hosted at http://mutdb.org/mutpred and 
calculates the probability of a deleterious mutation with corresponding hypothesis of disrupted 
molecular mechanism when found.  These algorithms were accessed during July/August 2010 
and evaluated using their respective default settings.  
 
Results 
Utilizing a strategy of k-fold cross validation (k=3), the correlation-based feature selection 
chose 23 properties from the original 544 amino acid attributes in AAindex.  These descriptors 
are summarized in Table 2.2.  Overall, 8 properties were chosen using feature selection in 3 out 
of 3 folds, while some 15 properties were seen in 2 out of 3 folds.  Amino acid properties relating 
to hydrophobicity or membrane buriedness, as well as positional or structural frequency seem to 
be representative of the features selected by this methodology. 
To evaluate classifier performance, the weighted average from 3 fold cross validation of 
sensitivity (true positive rate), specificity (true negative rate), and positive predictive value 
(precision) were calculated for each classifier algorithm.  Classifier performance is summarized in 
Table 2.3 as ranked by positive predictive value (PPV) or the percentage of variants classified as 
pathogenic that actually were pathogenic.  For this data set, ZeroR (zero rules - which selects the 
majority class by default), yielded a baseline performance of 55.7%.  The nearest neighbor, 





Table 2.2 Feature selection (n=23) from 544 amino acid properties from AAindex. 
 
 
Propertya     Original Source    PubMed IDb 
 
alpha NH chemical shifts    Bundi (1979)   7881270 
 
Normalized frequency of C terminal helix  Chou (1978)    364941  
Normalized frequency of chain reversal R    Tanaka (1977)    557155 
Normalized  positional frequency at helix termini N2   Aurora-Rose (1998)  9514257 
Partition coefficient      Garel (1973)    4700470 
Relative preference value at C2     Richardson (1988)   3381086 
Relative preference value at N1     Richardson (1988)  3381086  
Weights for beta sheet at the window position of 0   Qian (1988)   3172241 
Amino acid distribution      Jukes (1975)                237322         
Average relative fractional occurrence in A0(i)     Rackovsky (1982)  0903736 
Average relative probability of inner beta sheet   Kanehisa (1980)   7426680   
Composition       Grantham (1974)    4843792 
Effective partition energy      Miyazawa (1985)    2004114 
Free energy in alpha helical region     Munoz (1994)   7731949   
Frequency of the 3rd residue in turn   Chou (1978)    364941 
Helix formation parameters (delta delta G)     O Neil (1990)    2237415 
Hydrophobicity       Prabhakaran (1990)   2390062 
Membrane buried preference parameters    Argos (1982)   7151796 
Normalized frequency of beta structure    Nagano 1973    4728695 
Normalized frequency of coil     Nagano 1973    4728695 
Normalized positional frequency at helix termini Cc   Aurora-Rose (1998)  9514257 
STERIMOL maximum width of the side chain   Fauchere (1988)    3209351 
Zimm Bragg parameter sigma x 1.0E4    Sueki (1984)   1004141  
a Accessed August 2010 from http://www.genome.jp/aaindex/ 





other with 77.6%, 78.9%, 79.1%, and 81.4% respectively.  Naïve Bayes was the best performing 
algorithm with a PPV of 82.7%, a gain in performance of 27% over the ZeroR classifier. 
The machine learning algorithms constructed models that primarily used positional 
frequency and hydrophobicity related properties such as frequency of the 3rd residue in turn or 
membrane buried preference parameters as leading factors to classify the mutations.  This may 
reinforce the importance of mutations in key residues responsible for proper transmembrane 
placement and strategic cysteine residues responsible for normal kinase dimerization function 
[20].  In other words, location of the change is not equal across the length of the protein 
sequence.  Amino acid substitutions in key “hot spot” areas are thus more likely to result in 
pathogenic gain of function effects. Compared to the existing mutation prediction algorithms, we 
found that all the classifiers used here performed better than or similar to the well established 
algorithms (Table 2.3).  Analysis of the RET mutations using PolyPhen correctly identified 68 out  
  
Table 2.3 Summary of classification performance for machine learning algorithms. 
 
 
Algorithm  Algorithm  Algorithm  Positive 
Name   Sensitivity  Specificity       Predictive Value 
 
ZeroR      1.00      0.00         0.557 
 
IBk      0.896      0.674      0.776 
 
RandomForest        0.776      0.739      0.789 
 
SMO      0.914      0.696      0.791 
 
SimpleLogistic        0.826      0.761      0.814 
 
NaiveBayes     0.827      0.783      0.827 
 
 -----------------------------------------------------------------------------------------------------  
 
PolyPhena     0.597      0.920      0.541 
 
SIFTb      0.816      0.821      0.779 
 
MutPredc     0.767      0.823      0.843 






of 104 mutations as compared to the curated database entries (65% agreement).   The MutPred 
algorithm performed similarly with 64% agreement (67 out of 104). It was unable, however, to 
complete predictions for 33 of the 104 mutations, although results for the remaining curated 
entries yielded 67 out of 71 (94% agreement).  SIFT analysis correctly classified 75 of 104 cases 
when compared to the curated database for 72% agreement.  To demonstrate disagreement 
when comparing existing algorithms to curated outcomes, results for selected RET mutations are 
summarized in Table 2.4.   Discrepancies between the known phenotype and the existing 
prediction algorithms seemed to occur in cysteine related substitutions or where alignment to 
RET orthologs was not well conserved. 
 
Table 2.4 Comparison of mutation prediction for selected RET mutations. 
 
 
RET Gene Variant a  PolyPhen   SIFT   MutPred 
Curated Outcome   Predictionb  Predictionc  Predictiond 
  
G533C    probably   affects   Not 
(pathogenic)    damaging   function   available 
 
C609S    probably   affects   deleterious 
(uncertain)    damaging   function   (0.90) 
 
C611S    probably   affects   deleterious 
(pathogenic)    damaging   function   (0.90) 
 
C618G    probably   tolerated   deleterious 
(pathogenic)    damaging     (0.88) 
 
C620R    benign   tolerated   deleterious 
(pathogenic)          (0.75) 
 
C630R    probably   tolerated   deleterious 
(pathogenic)    damaging     (0.70) 
 
D631Y    probably   affects   deleterious 
(pathogenic)    damaging   function   (0.69) 
 
C634L    probably   tolerated   deleterious 
(pathogenic)    damaging     (0.69) 
 
S649L    possibly   tolerated   deleterious 
(pathogenic)    damaging     (0.66) 
 
G691S    benign   tolerated   benign 
(benign)          (0.20) 
a Curated RET variants from http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php. 
b Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
c Analyzed with default settings at http://sift.jcvi.org.  





One example that highlights the usefulness of predicting mutation severity was found in 
the RET codon 609.  Although several changes in the codon 609 are known to be pathogenic, the 
variant C609S is currently listed as an uncertain variant in the curated database.  The machine 
learning classifiers along with the mutation prediction tools labeled this variant as “predicted 
pathogenic,” “probably damaging” (SIFT), “affects protein function” (PolyPhen) and mutation 
(0.90), with a gain of glycosylation site (MutPred).  This example underscores the utility of 
computational prediction of mutations and suggests a need for careful evaluation of this C609S 
variant, including additional family outcome studies or further molecular confirmation of the 
resulting phenotype. 
When mutations are characterized by the difference between the values in several amino 
acid properties in the wild type and the mutated sequence, machine-learning classification can be 
used to accurately predict RET mutation status using primary sequence information only. Existing 
algorithms that are based on sequence homology (ortholog conservation) or protein structural 
data are not necessarily superior - at least for this specific genotype-phenotype. These results 
indicate that using physiochemical properties of amino acids to characterize mutations is 
important and may be more relevant than evolutionary sequence conservation.  Furthermore, the 
attributes found in AAIndex - in combination with feature selection - are a viable source of 
descriptors for use with machine learning tools and mutation prediction. Finally, several different 
types of algorithms worked similarly well, pointing to the robustness of this methodology.   
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Although reported gene variants in the RET oncogene have been directly associated with 
multiple endocrine neoplasia type 2 and hereditary medullary thyroid carcinoma, other mutations 
are classified as variants of uncertain significance (VUS) until the associated clinical phenotype is 
made clear.  Currently, some 46 nonsynonymous VUS entries exist in curated archives.  In the 
absence of a reliable method for predicting phenotype outcomes, this follow up study applies 
feature selected amino acid physical and chemical properties feeding a Bayes classifier to predict 
disease association of uncertain gene variants into categories of benign and pathogenic.  
Algorithm performance and VUS predictions were compared to established phylogenetic based 
mutation prediction algorithms.  Curated outcomes and unpublished RET gene variants with 
known disease association were used to benchmark predictor performance. Reliable 
classification of RET uncertain gene variants will augment current clinical information of RET 
mutations and assist in improving prediction algorithms as knowledge increases.  
 
Introduction 
Medical genetics involves diagnosis, management, and determining risk of hereditary 
disorders [1, 2].  The genotype:phenotype correlation of gene variants in disease is a major 
component of medical genetics.  In monogenic diseases, gene mutations are typically curated as 
either pathogenic or benign.  However, many gene variants must be classified as “unknown” or 
“uncertain” significance because they have not been clearly associated with a clinical phenotype.  
The outlay of time and labor to validate the disease association concerning a variant of 
uncertain significance (VUS) within the coding portion of a gene can be daunting and cost 
prohibitive [3, 4].  This is in large part, due to the communication between clinicians and 
laboratory geneticists needed to resolve these variants [5, 6].  To help bridge this 
genotype:phenotype gap, the use of machine learning classification algorithms to narrow the 
uncertain “grey area” between pathogenic and benign sequence variants warrants careful 
evaluation [7-10].  Reliable machine learning based classification may augment costly patient 
recruitment, family histories, and biochemical confirmation of a gene variant with no associated 
disease correlation [11-13]. 
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There are established methods for predicting mutation severity based on amino acid 
substitution penalties, structural disruption, sequence homology (ortholog conservation) or neural 
nets, such as PolyPhen [13], SIFT [14], MutPred [9] and PMut [15].  However, prediction 
algorithms are not always in agreement with curated data or each other [16-18].  Thus, there are 
opportunities to explore the use of other informatics approaches to this problem. Machine 
learning methods that can be trained on data available in well-curated gene variant collections 
may be promising tools to improve the predictive capabilities available to the research 
community.  
The human RET gene (REarranged during Transfection) is located on chromosome 
10q.11 codes for 20 exons.  The transcript length is 5,659 bps and translates to the 1,114 amino 
acid residue protein (UniProt RET_HUMAN, #P07949) as shown in Figure 3.1.  The gene 
belongs to the cadherin superfamily and encodes a receptor tyrosine kinase which functions in 
signaling pathways for cell growth and differentiation.  RET plays a critical role in neural crest 
development. It can also undergo oncogenic activation in vivo and in vitro by cytogenetic 
rearrangement. It can be further classified by Gene Ontology (GO) categories 
(www.geneontology.org) of biological process of homophilic cell adhesion, posterior midgut 
development, and protein amino acid phosphorylation.  Its GO annotated cellular location is 
component integral to membrane and the GO category of molecular functions lists ATP binding, 
calcium ion binding and transmembrane receptor protein tyrosine kinase activity.  Functional 
domains of the RET protein are also summarized in Figure 3.1. 
 
Figure 3.1 Schematic of the full length 1114 amino acid RET protein showing the signal 
peptide (SP, residues 1-24), cadherin domain (CAD, residues 191-270),  transmembrane 
domain (TM, residues 636-652),  and tyrosine kinase motif (Kinase, residues 724-1005). 
SP CAD
KinaseTM
[724 – 1005] [1114][636-652][191-270][1-24]
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RET is essential for the development of the sympathetic, parasympathetic and enteric 
nervous systems.  Disruption of function by germline mutations in RET have been associated with 
several diseases in humans including three related inherited cancers: multiple endocrine 
neoplasia type IIA (MEN2A), multiple endocrine neoplasia type IIB (MEN2B), and familial 
medullary thyroid carcinoma (FMTC). [19, 20]   RET has also been implicated in congenital 
aganglionosis (absence of enteric nerve cells) in the gastrointestinal tract (Hirschsprung's 
disease) lack of the neuroenteric plexi impairs smooth muscle activity of the intestines 
(particularly the colon) resulting in refractory constipation. [21] 
Although well understood codon changes often guide patient therapy or surgical options 
[22],  RET gene variants may vary in functional severity, where some are reported as benign, 
some pathogenic, and some of uncertain significance.  Curated RET oncogene mutations have 
been recently reported by Margraf et al. [23]  The disease classification of RET gene variants has 
been curated as benign (6%), pathogenic (52%) and VUS (42%), meaning unknown or uncertain 
association with disease or phenotype outcome. This archive currently hosts 146 RET variants, 
including 62 VUS entries that can be accessed at http://www.arup.utah.edu/database/. 
Accurate prediction of disease association for novel mutations and uncertain gene 
variants is of great importance to medicine and biology.  Informatics tools for predicting disease 
severity of uncertain gene variants will aid in the improvement of genetically-informed patient 
care.  With a rapidly growing number of on-line resources for gene variants collections, the 
opportunity to apply machine learning algorithms to well curated disease causing gene sets 
becomes increasingly desirable.   
The absence of any gold standard for predicting phenotype severity in uncertain gene 
variants prompts two questions.  Are algorithms trained specific to a gene/disease setting more 
appropriate to use than generalized on-line prediction tools?  Does agreement between several 
and varying algorithms influence clinician decision-making?  This study expands a recently 
reported algorithm, we here term Primary Sequence Amino Acid Properties (PSAAP), which uses 
feature selected amino acid physicochemical properties of primary amino acid sequence. [24]  
This previous work detailed algorithm performance using only gene variants with known disease 
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association, while here we report applying the PSAAP algorithm classification for pathogenicity of 
novel and uncertain gene variants found in the RET proto-oncogene into categories of benign or 
pathogenic. The PSAAP algorithm performance has also been compared to four well-established 
prediction tools available on-line and agreement between algorithms summarized. 
 
Methods 
Nonsynonymous RET variants were characterized by physicochemical differences in 
primary amino acid sequence resulting from the mutation.  Attributes of mutation status were 
characterized using values of 544 physical, chemical, conformational, or energetic properties 
(AAindex v9.4). [25]   AAindex is a database of numerical indices representing various 
physicochemical and biochemical properties of amino acids and pairs of amino acids.  For each 
RET variant, matrices of delta values for each biochemical property of the substituted amino acid 
were calculated by Python scripting and the resulting mutation described by an array of variables 
archived using SQL - where each matrix corresponds to the absolute value of the difference 
between the value of the property in the amino acid present in the wild type and the one in the 
mutant.    
As previously described, representative algorithms from different categories of 
classification (such as nearest neighbor, bayes, regression, rule-based and support vector 
machine) were evaluated for their ability to correctly predict mutation status in the training set. 
[24]  Briefly, a clinically curated set (n=84) of nonsynonymous RET mutations with known 
pathogenicity was used to train and test machine learning classification algorithms.  Although 
training and test sets included different disease subtypes such as MEN2A (n=40), MEN2B (n=3), 
FMTC (n=5), MEN2A and FMTC (n=36) - class labels of “pathogenic” and “benign” were used to 
describe all curated disease association.  Random selection was used to build a 2/3 training set 
(n=56) and 1/3 test set (n=28).   Attribute selection (feature selection) was performed during 
classification training/testing. Machine classification algorithms were implemented using the 
Weka software package (v3.6). [26]  When a given classification algorithm produced posterior 
probabilities of mutation status, we assigned each variant's mutation status according to the 
higher posterior probability (Weka's default behavior).   
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The PSAAP algorithm performance was evaluated using the test set, with sensitivity (true 
positive rate), specificity (true negative rate), and positive predictive value (precision) calculated.    
A data set of non-synonymous RET uncertain variants (n=46) was then analyzed using our 
PSAAP (Naïve Bayes, gene-specific trained) classification algorithm.  The workflow of our 



















Figure 3.2 Overview of the PSAAP classifier workflow, highlighting the gene-
specific algorithm training on clinically curated disease association. 
 
Next, both curated RET mutations (known disease association) and RET uncertain 
variants (VUS data) were analyzed and compared using four existing mutation prediction 
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algorithms.  These established prediction tools are mainly based on phylogenetic properties such 
as sequence homology, amino acid substitution penalties or structural disruption.  MutPred 
(mutdb.org/mutpred) [9], PolyPhen (genetics.bwh.harvard.edu/pph) [13], SIFT (sift.jcvi.org) [14], 
and PMut (mmb2.pcb.ub.es:8080/PMut) [15] were accessed during July/August 2010. Both 
curated RET variants and RET VUS entries were evaluated using respective default settings. 
 Finally, several unpublished RET disease variants (n=5) with known pathogenic 
outcomes (by surgical pathology, molecular testing and family history) were identified during 
routine genetic testing at ARUP Laboratories.  This nascent set of RET variants was also 
analyzed and compared by all prediction algorithms to further benchmark some standard of 
performance and precision.   Data and methods used for this study were approved by the 
Institutional Review Board of the University of Utah (IRB #00035757). 
 
Results 
The independent test set of RET curated mutations was used to evaluate performance of 
different categories of classifier algorithms.  The best performing algorithm (using Weka) was 
Naïve Bayes.  Algorithm metrics for this novel Bayes classifier of RET disease outcome were 
calculated using the above test set data.  Evaluation of the classifier yielded a sensitivity of 0.938, 
specificity of 0.867 and positive predictive value (precision) of 0.883.  Performance for our 
Primary Sequence Amino Acid Properties (PSAAP) classifier is summarized in Table 3.1.  A 
benchmark of prediction performance for the established algorithms (MutPred, PolyPhen, PMut 
and SIFT) was also performed using curated RET gene variants with known disease outcomes.  
Following the 88% of the PSAAP classifier, MutPred was next closest to predicting the correct 
disease outcomes for the known RET variants with 84% precision.  PolyPhen yielded the highest 
specificity for RET variant disease association of 92%, yet had the lowest precision at 54%.   
PMut correctly predicted gene variant disease outcomes with 72% precision but had the lowest 
specificity at 59%.  Table 3.1 also summarizes performance metrics (sensitivity, specificity, 






Table 3.1 PSAAP algorithm performance of predicted phenotypes using curated RET mutations. 
 
   
PSAAP  MutPred  PolyPhen  PMut   SIFT   
  Predictiona Predictionb Predictionc Predictiond Predictione  
 
Sensitivity 0.938  0.767  0.597  0.783  0.816     
  
Specificity 0.867  0.823  0.920  0.591  0.821   
 
Precision 0.883  0.843  0.541  0.723  0.779  
  
a Primary Sequence Amino Acid Properties (PSAAP) algorithm. 
b Analyzed with default settings at http://mutdb.org/mutpred. 
c Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
d Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
e Analyzed with default settings at http://sift.jcvi.org. 
 
Next, evaluation of RET non-synonymous VUS mutations (n=46) was performed using 
our recently reported  algorithm .[24]  The PSAAP algorithm classified 22 of the uncertain variants 
as pathogenic, while the remaining 24 fell within the benign grouping. For those variants 
classified as predicted pathogenic, the PSAAP algorithm estimated confidence remained above 
90%.  The classifier predicted disease outcome using our algorithm is listed in Table 3.2.   
Results from analysis of the RET uncertain gene variants (VUS) using the established 
on-line prediction tools are also summarized in Table 3.2, with predicted pathogenic variants 
bolded and ranked by agreement.  The MutPred tool calculates the probability of a deleterious 
mutation and corresponding hypothesis of disrupted molecular mechanism.  We used MutPred's 
default probability cutoff of 0.75 for differentiating between benign and disrupted/pathogenic 
mutations.  Our PSAAP algorithm agreed with MutPred in 16 benign and 8 pathogenic predictions 
for 52% agreement (24 out of 46).  PolyPhen has outcomes of “benign,” “possibly damaging” and 
“probably damaging.” The PSAAP classifier agreed with PolyPhen in 13 benign and 22 
pathogenic predictions for 76% agreement (35 out of 46).  PMut yields outcomes of “pathological” 
or “neutral” and a corresponding reliability metric (lower is better). Our PSAAP trained algorithm 
was in concordance with PMut in 13 benign and 14 pathogenic predictions for 58% agreement 
(27 out of 46).  The SIFT algorithm gives outcomes of “tolerated” and “affects protein function.”  
Our algorithm agreed with SIFT in 19 benign and 16 pathogenic predictions for 76% agreement 
(35 out of 46).   
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Table 3.2 Algorithm agreement for RET uncertain gene variants and predicted pathogenicity. 
 
 
RET uncertain PSAAP  MutPred  PolyPhen     SIFT                PMut  
gene variant Predictiona Predictionb Predictionc Predictiond Predictione  
5/5 agreement 
A510V  benign  benign  benign  tolerated  neutral  
R600Q  benign  benign  benign  tolerated  neutral  
K603Q  benign  benign  benign  tolerated  neutral  
E632K  benign  benign  benign  tolerated  neutral  
A640G  benign  benign  benign  tolerated  neutral  
V648I  benign  benign  benign  tolerated  neutral  
Y791N  pathogenic disrupted prob damaging    affects function pathological   
E843D  benign  benign  benign  tolerated  neutral  
R844L  pathogenic disrupted prob damaging    affects function pathological   
R844W  pathogenic disrupted prob damaging    affects function pathological   
R886W  pathogenic disrupted prob damaging    affects function pathological  
R912Q  pathogenic disrupted prob damaging    affects function pathological    
4/5 agreement 
C611S  pathogenic disrupted prob damaging affects function neutral  
D631G  pathogenic benign  prob damaging     affects function pathological   
E805K  benign  disrupted prob damaging     affects function pathological   
S819I  pathogenic disrupted prob damaging     affects function neutral  
R833C  pathogenic benign  prob damaging     affects function pathological   
S904C  pathogenic benign  prob damaging     affects function pathological    
S904F  pathogenic benign  prob damaging     affects function pathological   
3/5 agreement 
Y606C  pathogenic benign  prob damaging tolerated  pathological  
C531R  pathogenic benign  prob damaging tolerated  pathological  
G533S  pathogenic benign  prob damaging affects function neutral  
D631A  pathogenic benign  prob damaging affects function neutral  
D631V  pathogenic benign  prob damaging affects function neutral     
R635G  pathogenic benign  prob damaging tolerated  pathological  
P841L  pathogenic benign  prob damaging tolerated  pathological  
L881V  benign  disrupted prob damaging affects function neutral  
K907M  pathogenic benign  prob damaging affects function neutral  
2/5 agreement 
C630S  pathogenic benign  prob damaging tolerated  neutral  
D631E  benign  benign  prob damaging tolerated  pathological   
S649L  pathogenic benign  prob damaging tolerated  neutral  
H665Q  benign  benign  prob damaging tolerated  pathological   
R844Q  benign  benign  prob damaging tolerated  pathological   
M848T  benign  benign  prob damaging     tolerated pathological   
I852M  benign  benign  prob damaging     affects function neutral  
K907E  benign  benign  prob damaging     affects function neutral  
1/5 agreement 
G321R  benign  benign  benign  tolerated  pathological   
E511K  benign  benign  benign  tolerated  pathological   
D631N  benign  benign  benign  tolerated  pathological   
A641S  benign  benign  poss damaging tolerated  neutral  
K666N  benign  benign  prob damaging     tolerated neutral  
R770Q  benign  benign  prob damaging     tolerated neutral  
N777S  benign  benign  poss damaging     tolerated neutral  
V778I  benign  benign  benign   affects function neutral  
E818K  benign  benign  poss damaging  tolerated neutral  
a Primary Sequence Amino Acid Properties (PSAAP) algorithm. 
b Analyzed with default settings at http://mutdb.org/mutpred. 
c Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
d Analyzed with default settings at http://sift.jcvi.org. 
e Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
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Of special interest, for predicted RET benign variants, 7 of 24 agreed across all 
algorithms, while only 6 of 22 predicted pathogenic RET variants showed agreement across the 
different methods.  Although only 13 out of 46 (28%) were concordant, these variants may count 
as having a higher degree of confidence in prediction due to the varied methodologies and basis 
of classification.   Importantly, the focus of molecular research and clinical efforts could therefore 
be directed to this prioritized listing of RET uncertain variants.  Curated variants are shown 
mapped across the length of the protein in Figure 3.3A.  This graphing visually highlights the 
cysteine rich region just prior to the transmembrane domain, and the transmembrane domain 
itself which contain the majority of pathogenic variants.  Our predictions for the uncertain RET 
variants (VUS) are also mapped by location across the length of the protein as added into Figure 
3.3B.    
Finally, several unpublished RET gene variants with known pathological (MEN2) 
outcomes (n=5) were identified during routine genetic testing at ARUP Laboratories.  To further 
benchmark RET mutation prediction, all five algorithms were used to classify this set of not yet 
seen variants.  Our novel Bayes trained PSAAP classifier correctly identified all five variants as 
pathogenic.  PMut called three disease causing variants correctly, but classified two others as 
“neutral” mutations, when in fact these changes were known to be associated with disease.  
PolyPhen also correctly identified three as probably damaging (pathogenic), but missed classified 
the same two variants as PMut.  SIFT predicted four of these variants would affect function 
(pathogenic), but called one of the same variants “tolerated.”   MutPred correctly predicted all five 
as pathogenic.   
 
Discussion 
Mutations in the RET proto-oncogene have been directly associated with MEN2 and 
hereditary medullary thyroid carcinoma, and provide guidance for patient care.  Accurate 
classification of phenotype severity for novel mutations and uncertain variants as relating to 
disease is of great importance to proper patient care.  Although correlation of genotype-




Figure 3.3 Schematic of the RET protein with A) clinically curated variants and B) 
predicted disease association for uncertain variants mapped across protein location.  The 
phenotype overlay shows regions of reported MEN2A, MEN2B and FMTC disease. 
 
specific mutation-guided management strategies, appropriate caution is justified when clinicians 
are asked to trust computational outcomes for determining patient care. [6] 
On-line mutation prediction tools have been available for many years.  Prediction tools 
such as PolyPhen [13] and SIFT [14] are primarily based on multiple alignment and amino acid 
substitution penalties.  More recently, MutPred [9] which calculates probability of deleterious 








MEN2BMEN2A MEN2A and FMTC
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trained on human mutations.  We recently reported classification of curated RET gene variants 
using primary amino acid sequence properties and Naïve Bayes.[24]  A key feature to highlight is 
the fact that the PSAAP algorithm relies on Bayes probability trained on gene-specific and 
clinically curated disease outcomes.  Comparison of this recent PSAAP algorithm with 
established on-line prediction tools may improve our understanding of predicting mutation status 
in the RET proto-oncogene. 
Sorting Intolerant From Tolerant (SIFT) was first published in 2003 by Ng and Heinikoff 
from work done at the Fred Hutchinson Cancer Research Center in Seattle. [14]  The algorithm 
predicts whether an amino acid substitution will affect the function of a protein based on both 
sequence homology to various orthologs and physical properties of amino acids.   SIFT is a 
multistep procedure that (1) searches for and chooses similar sequences, (2) makes an 
alignment of these sequences, and (3) calculates scores based on the amino acids appearing at 
each position in the alignment.   It was initially developed and trained on nsSNP data sets from 
LacI, Lysozyme, and HIV protease. [27]  This algorithm works especially well when adequate 
numbers of sequence homologs are available for multiple alignment.  Conversely, poor 
performance is seen when multiple alignment in not reliable or completely unavailable. 
Polymorphism Phenotyping (PolyPhen) is an EMBL based tool from 2002 from 
Ramensky et al. [13]  It was developed to predict the possible impact of an amino acid 
substitution on the structure and function of a human protein using physical and comparative 
considerations.  It was originally developed from a set of disease-causing mutations in human 
proteins with known structures extracted from the SWISS-PROT database, and correlated to the 
Online Mendelian Inheritance in Man (OMIM) database. [28]  Since the algorithm relies on 
predicted structural disruption, it works especially well where protein structure is known and less 
reliable when a solved protein structure is not available. 
MutPred is a recently developed prediction algorithm by Li, Mooney and Radivojac. [9]   It 
builds on the established SIFT method but offers improved classification accuracy based upon 
protein sequence, and models changes of structural features and functional sites between wild-
type and mutant sequences with output of probabilities of gain or loss of structure and function.  It 
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was trained on a set of disease SNPs from cancer and the OMIM disease archive.  This predicted 
disruption of molecular function again work especially well for well studied proteins, where 
homolog and solved structure is available. 
PMut was first published in 2005 by the Molecular Modeling Unit at the Institut de 
Recerca Biomédica, Parc Científic de Barcelona, Spain. [15]  It is based on a two layer neural 
network and was trained using human mutational data.  It allows for either prediction of single 
point amino acidic mutations or scanning of mutational hot spots.  Results are obtained by 
alanine scanning, identifying massive mutations and genetically accessible mutations.   A 
graphical interface for Protein Data Bank (PDB) structures, when available, and a database 
containing hot spot profiles for all non-redundant PDB structures are also accessible from the 
PMut server. 
Benchmarking the established prediction algorithms with curated RET variants and 
associated MEN2 disease demonstrates our PSAAP classifier model compares very well to other 
established prediction tools.  A distinguishing feature of the PSAAP model  herein reported is the 
algorithm was trained specifically to curated RET disease outcomes, as summarized in Figure 
3.2.  This is in contrast to the less robust curated collections of mutations such as OMIM or 
dbSNP.  Further, no homolog alignment or solved protein structure is necessary. Rather, it relies 
on primary sequence information only - with calculated delta matrices of substituted amino acid 
properties , and is therefore not limited to scenarios where SIFT or PolyPhen (and others) have 
traditional been used.  These facts may explain the improved performance when classifying RET 
variants as compared to generalized prediction tools available on-line.   
Ranking agreement of predicted phenotype severity across several complimentary 
algorithms may provide an additional level of clinical confidence in computational classifiers.  At a 
minimum, these five all-in-agreement “predicted pathogenic” RET variants warrant closer 
investigation by traditional and molecular techniques.  Furthermore, algorithm agreement in a 
clinical setting may be just as important for “benign” as it might be for “pathogenic.”  
Personalized treatment in genomic medicine cannot advance until questions such as 
what was found, what does it mean and what to do about it can be answered for each individual 
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patient and genetic test result.  Among the key features critical for a decision support framework 
in clinical genetic testing is a reliable phenotype classification tool and scoring metric to predict 
consequences of a variation that alters protein structure.   For these uncertain gene variants, the 
in-house algorithm trained specifically on available RET curated outcomes seems to outperform 
well-established and generalized prediction tools available on-line.  More importantly, agreement 
between several predictors may provide research priority for novel and uncertain gene variants. 
The use of machine learning algorithms to classify uncertain gene variants in disease is a 
promising tool to strengthen our underlying knowledge of disease pathogenesis.  Software 
algorithms to better classify gene variants of uncertain significance are necessary to move 
translational research forward.  This follow up study used the PSAAP algorithm to “reclassify” 46 
variants of uncertain significance within the RET proto-oncogene into categories of benign or 
pathogenic.  This novel application of classification algorithms for computational prediction of 
phenotype severity in uncertain gene variants could be generally applied to any gene-disease 
setting where a corpus of curated gene variants are trusted and where reported mutations impact 
clinical care.  
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Accurate interpretation of gene test results is a key component in customizing patient 
therapy for personalized medicine.  As electronic medical records begin to incorporate genetic 
information, gene variant annotation has far reaching implications when informing physicians on 
the most adequate course of treatment.   While a growing numbered of authoritative clinical 
repositories with gene variants and clear association to disease phenotype are beginning to 
emerge, still there are many more gene variants that have not been annotated with disease 
association.  Computer based mutation severity prediction models derived from clinically curated 
gene-disease data sets can help bridge this uncertainty gap for novel and uncertain gene 
variants.  Here we present the evaluation of “gene-specific” and “all-gene” predictor models 
based on a Naïve Bayesian classifier for 20 gene-disease data sets, containing 3,986 variants 
with well characterized patient conditions. 
 
Introduction 
Personalized medicine implies that all relevant clinical information is available on demand 
for effective patient treatment.  Proper interpretation of gene test results is a key component in 
customizing patient therapy.  Efforts such as the Human Variome Project, 1000 Genomes and 
NCBI Genetic Testing Registry highlight a growing interest in annotation and clinical interpretation 
of gene variants in human disease.[1-3]  As genetic information is incorporated into the electronic 
medical record, new decision support approaches are needed to provide clinicians with a 
preferred course of treatment.[4] For decision support rules to add value, the clinical relevance of 
laboratory information must be well understood.   
Furthermore, with rapidly evolving technologies such as SNP chip genome wide 
association studies and next-generation sequencing, genomic analysis is trending faster and 
cheaper and yielding much larger data sets.  As such, gene variants are being discovered at an 
almost astronomical pace, with one recent report finding an average of 3 million variants per 
personal genome.[5] 
Unfortunately, an increasingly apparent gap exists between rapidly growing collections of 
genetic variation and practical clinical implementation.  Although collections of human genome 
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variation have been underway for years, authoritative repositories of gene variants with clear 
association to disease phenotype are only now beginning to emerge.[6-10]  This is in contrast to 
existing collections of genome-wide mutations such as dbSNP[11] or OMIM[12] that are not 
curated using consistent, systematic or transparent methods. Focusing computer predictive 
algorithms on authoritative and specific gene-disease settings has the potential to bridge this 
knowledge gap. 
Prediction algorithms for computing mutation severity have been used for many 
years.[13-16]  Despite their use in laboratories, they do not have sufficient accuracy to predict 
disease phenotype to the degree necessary to be clinically applicable. This allows opportunities 
to explore the application of advanced informatics approaches to this problem.   This study 
expands the recently reported Primary Sequence Amino Acid Properties (PSAAP) algorithm [17], 
which uses a classification approach and amino acid physicochemical properties of the primary 
amino acid sequence to predict pathogenicity of novel and/or uncertain gene variants.  To date, 
the approach has been applied only to the RET proto-oncogene. 
To evaluate the generalizability of our gene-specific PSAAP algorithm, we extend its use 
to a set of 20 genes with clinically curated disease variants. The analyses also compare the 
effectiveness of generic gene versus gene specific approaches using a minimum (non-redundant) 
set of amino acid properties to describe exonic non-synonymous variants coupled with evaluation 
of overlap and/or trends of biochemical properties of mutation. 
 
Methods 
Gene variant data relating well-characterized patient condition to genotype (genotype-
phenotype) were assembled from multiple sources including: cystic fibrosis mutation database 
curated by Ruslan Dorfman (Hospital for Sick Children, Toronto)[18]; BioPKU database curated 
by Nenad Blau (University Children’s’ Hospital, Zurich)[19]; neurofibromatosis type 1 database 
curated by Ophélia Maertens (Center for Medical Genetics, University Hospital, Ghent) and 
Collagen, type IV, alpha 5 (COL4A5) Mental Retardation Database curated by Judy Savige 
(Department of Medicine, University of Melbourne) as hosted by Leiden Open Source Variation 
Database (LOVD)[20-22]; biotinidase (BTD) curated by Barry Wolf (Medical Genetics, Henry Ford 
47 
 
Hospital, Detroit)[23]; aryl hydrocarbon receptor interacting protein (AIP) curated by Rodrigo 
Toledo (Endocrine Genetics Unit, University of Sao Paulo Medical School) (personal 
communication); Disease Databases hosted by Department of Pathology, University of Utah 
School of Medicine[24] and genetic testing results archived at ARUP Laboratories (Salt Lake 
City).  The clinically curated gene-disease data sets (n=20) containing some 3986 curated 
variants are summarized in Table 4.1.   
This 20 gene collection contained 1639 exonic non-synonymous SNP’s (nsSNP) with 
known outcomes of benign (n=607) and pathogenic (n=1032).  The gene variants were 
characterized using physicochemical properties of the substituted amino acid as previously 
reported. [25]  Briefly, all nsSNP’s were characterized by the differences in their physical, 
chemical, conformational, or energetic properties between the amino acid present in the wild type 
and the variant.   Descriptors were attributes derived from 544 amino acid properties archived in 
AAindex v9.4. [26]  AAindex is a database of numerical indices representing various 
physicochemical and biochemical properties of amino acids.  For each gene variant, vectors of 
delta values for each biochemical property of the substituted amino acid were calculated and the 
resulting mutation described by an array of variables, corresponding to the absolute value of the 
difference between wild type and mutant. 
Next, based on curated clinical outcomes of benign or pathogenic, the minimum (non-
redundant) set of amino acid properties needed to describe pathogenicity of gene variants was 
investigated using the attribute selection methods of correlation-based feature subset selection, 
SVM-RFE and Relief-F.   Thresholds of 95% (or 0.95) for Greedy-Stepwise and Ranker were 
used during this analysis. All feature selection and Naïve Bayes classification was implemented 
using the Weka software package.[27] 
For each of the 20 genes, random selection was used to build a 2/3 training and a 1/3 
test sets with known class labels (benign, pathogenic) and constructed to keep the original ratio 
of benign and pathogenic constant.  Next, based on curated clinical classification of benign or 
pathogenic, algorithm training and pathogenicity prediction was performed gene-by-gene.  Gene-
specific models were also tested for prediction of other gene-disease outcomes, by using the  
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Table 4.1.  Clinically-curated gene variant data sets (n=20) with known disease association. 
 
Gene Symbol   Gene Name                Curated    Exonic 
Biological Function  Disease Association              Variants    nsSNPs 
 
ACVRL1    activin A receptor type II-like 1   332   192 
activin receptor activity, type 1 hereditary hemorrhagic telangiectasia 
 
AIP    aryl hydrocarbon receptor interacting protein    102 84 
transcription coactivator activity familial pituitary adenoma     
     
BTD    biotinidase     155 105 
biotin carboxylase activity   biotinidase deficiency 
 
CFTR    cystic fibrosis transmembrane conductance regulator 252 121 
chloride channel regulator activity  cystic fibrosis 
 
COL4A5    collagen, type IV, alpha 5    600 266 
extracellular matrix structural X-linked Alport syndrome (hereditary nephritis)  
 
ENG    endoglin      397 124 
TGF β receptor activity  hereditary hemorrhagic telangiectasia 
 
GALT    galactose-1-phosphate uridylyltransferase  247 168 
uridylyltransferase activity   galactosemia 
 
GJB2    gap junction protein, beta 2 (connexin 26)  61 43 
gap junction channel activity hereditary sensorineural hearing loss 
 
MECP2    methyl CpG binding protein 2   26 14 
transcription co-repressor activity Rett syndrome 
 
MSH2    mutS homolog 2     89 8 
guanine/thymine mispair binding  hereditary nonpolyposis colonrectal cancer 
 
MSH6    mutS homolog 6     34 10 
guanine/thymine mispair binding  hereditary nonpolyposis colonrectal cancer 
 
NF1    neurofibromin 1     125 121 
Ras GTPase activator activity  neurofibromatosis type 1 
 
PAH    phenylalanine hydroxylase    730 126 
phenylalanine catabolism  phenylketonuria (PKU) 
 
PLOD1    procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 34 12 
procollagen-dioxygenase activity  Ehlers-Danlos syndrome type VI 
 
PMS2    postmeiotic segregation increased 2  348 45 
mismatched DNA binding  hereditary nonpolyposis colorectal cancer 
 
RET    ret proto-oncogene    146 97 
receptor kinase activity   multiple endocrine neoplasia,  (MTC)  
 
SLC22A5   solute carrier family 22, member 5   95 57 
carnitine transporter activity  primary carnitine deficiency 
 
SMAD4    SMAD family member 4    86 23 
transcription activator activity  juvenile polyposis syndrome, pancreatic cancer 
 
SPINK1    serine peptidase inhibitor, Kazal type 1  73 5 
endopeptidase inhibitor activity  hereditary pancreatitis 
 
SPRED1   sprouty-related, EVH1 domain containing 1  54 18 
inactivation of MAPK activity Legius syndrome (neurofibromatosis type-like syndrome)   
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training set of one gene and a test set from a second gene.  In a similar fashion, an “all-gene” 
model was constructed using all the available training sets. This “all-gene” model was then tested 
by making gene-by-gene predictions.  Due to a low number of nsSNP exonic substitution 
variants, five genes (MECP2, MSH2, MSH6, PLOD1 and SPINK1) were only included in the all-
gene training set, and not used for gene-specific training.  Algorithm performance was evaluated 
using each gene test set, with sensitivity (true positive rate), specificity (true negative rate), and 
positive predictive value (PPV) calculated for each classifier algorithm and gene-specific and all-
gene permutations.    Lastly, our PSAAP gene-specific algorithm performance was compared to 
well established prediction algorithms such as SIFT[13], PolyPhen[14], PMUT[15] and 
MutPred[16].   
For all genes, the full length protein isoform was used for this study.  Splice variants were 
not considered.  All gene variants were mapped to their reference amino acid sequence from 
UniProtKB (http://www.uniprot.org).  Protein reference sequences are summarized in Table 4.2.  
 
Table 4.2 Reference amino acid sequence from UniProtKBa. 
 
 
Gene symbol UniProt # Protein name   AA length Date accessed          
ACVRL1  P37023  ACVL1_HUMAN  503  December 6, 2010 
AIP   O00170  AIP_HUMAN  330  January 5, 2011 
BTD   P43251   BTD_HUMAN  543  December 6, 2010 
CFTR  P13569   CFTR_HUMAN   1480  December 6, 2010 
COL4A5  P29400   CO4A5_HUMAN   1685  December 7, 2010 
ENG   P17813   EGLN_HUMAN   658  December 7, 2010 
GALT   P07902   GALT_HUMAN   379  December 7, 2010 
GJB2   P29033   CXB2_HUMAN   226  December 7, 2010 
MECP2   P51608   MECP2_HUMAN  486  December 7, 2010 
MSH2   P43246   MSH2_HUMAN   934  December 8, 2010 
MSH6   P52701   MSH6_HUMAN   1360  December 8, 2010 
NF1   P21359   NF1_HUMAN   2839  January 5, 2011 
PAH   P00439   PH4H_HUMAN   452  January 6, 2011 
PLOD1   Q02809   PLOD1_HUMAN   727  December 9, 2010 
PMS2   P54278   PMS2_HUMAN   862  December 9, 2010 
RET   P07949   RET_HUMAN   1114  December 9, 2010 
SLC22A5  O76082   S22A5_HUMAN   557  December 9, 2010 
SMAD4   Q13485   SMAD4_HUMAN  552  January 7, 2011 
SPINK1   P00995   ISK1_HUMAN  79  December 9, 2010  








Overall, the performance of the PSAAP gene-specific trained algorithm was significantly 
better (8% to 13%) than the “all-gene” model, with p values of 0.00001 (sensitivity), 0.00113 
(specificity) and 0.00012 (PPV) as shown in Figure 4.1.  For the genes evaluated, the PPV of our 
gene-specific PSAAP algorithm averaged 89% (82% to 94%).  This was on average 11% higher 
than the “all-gene” model where PPV ranged from 62% to 86%.  The one exception was 
SLC22A5, where PPV remained constant.  Sensitivity averaged 13% higher than the “all-gene” 
model, except for SPRED1 which was 6% decreased.  Specificity was also generally improved 
(9% average) for all but PMS2 (no increase) and NF1, which was 5% decreased.   
For the genes studied here, the PSAAP gene-specific prediction performs well.  PPV 
values are displayed in Table 4.3.  The self against self is plotted on the diagonal in blue with 
ppv>80 bolded. Other gene predictor performance with PPV above 80 is shaded in orange.  
Interestingly, gene-specific prediction models do not seem to generalize well – even across 
similar protein functional families.  For instance, Table 4.3 shows that the RET kinase trained 
model (94% PPV) performed lower for the ACVRL1 kinase (84% PPV) while the ACVRL1 trained 
predictor (88% PPV) only predicted RET with 80% PPV.  Additionally, the carboxylase enzyme 
BTD (91% PPV) only predicted the hydroxylase PAH gene variant outcome with 76% PPV, while 
the PAH trained predictor (89% PPV) only predicted BTD with 59% PPV.  It is notable, however, 
that 3 out of 15 genes (SPRED1, NF1 and GALT) yielded comparable numbers for predicting 
disease association across other genes.   
The improved performance of gene-specific algorithms may be explained in part by an 
important observation that biochemical and/or structural characteristics of mutation specific to one 
disease may be lost or diluted when combined with large genomewide data sets for algorithm 
development.  This can be illustrated by plotting nonsynonymous variants specific to a gene-
disease condition as compared to random amino acid substitutions (Figure 4.2).   When 1000 
random amino acid changes were plotted (Figure 4.2A), a wide distribution evenly covers the 



































































































































































































Figure 4.1 Performance of the gene-specific algorithm (PSAAP) as compared to 
an all-gene algorithm plotted to show A) sensitivity, B) specificity and C) positive 
predictive value (PPV).  Significance of any improvement was calculated using a 




Table 4.3 Positive prediction value (PPV) of gene-specific algorithms to predict pathogenicity in 
other genes, where the blue diagonal represents gene-specific prediction.  Bolded results shown 
in tan squares denote PPV > 80%. 
ACVRL1 AIP BTD CFTR COL4A5 ENG GALT GJB2 NF1 PAH PMS2 RET SLC22A5 SMAD4 SPRED1
ACVRL1 88 83 74 70 84 77 79 79 85 74 76 80 81 72 78
AIP 72 91 62 62 69 59 66 55 68 57 65 63 62 58 62
BTD 77 79 91 77 85 73 82 81 85 76 70 70 71 81 85
CFTR 53 62 56 90 56 54 59 55 51 54 47 60 53 57 61
COL4A5 47 58 62 51 88 83 55 61 52 57 46 56 57 56 50
ENG 48 47 62 57 84 92 49 55 51 56 50 60 54 60 61
GALT 83 82 85 80 77 74 86 77 80 81 85 80 81 77 84
GJB2 67 56 73 54 56 70 73 87 55 66 69 64 62 56 71
NF1 90 76 84 75 90 89 75 79 89 83 75 73 78 81 84
PAH 62 74 59 55 63 58 64 60 82 89 58 71 65 60 59
PMS2 66 62 63 61 61 70 55 69 62 71 88 66 70 63 56
RET 84 69 62 42 64 57 46 72 66 72 45 94 49 68 59
SLC22A5 74 66 63 73 72 71 69 68 73 70 68 72 82 71 81
SMAD4 49 53 65 61 49 64 47 53 67 67 56 52 64 84 67










characteristic trends of specific residues and frequency of substitution are readily seen (Figure 
4.2B).  Disease-specific examples of this concept are shown in Figure 4.3.  In the RET proto-
oncogene (associated with medullary thyroid cancers), some 79% of all pathogenic changes were 
found to involve cysteine (C) to some other residue (X) as displayed in Figure 4.3A.  In the 
COL4A5 gene (associated with Alport syndrome), 84% of pathogenic changes involve glycine (G) 
to other residues (X) as shown in Figure 4.3B. To confirm this trend, further experiments should 
be performed as additional curated gene-disease collections become available. 
 
Figure 4.2 Specificity of pathogenic mutations demonstrated by plotting A) simulated 
random amino acid substitutions (n=1000) showing a wide distribution covering the entire 
range of possible substitutions and B) known pathogenic mutations (n=1000) showing 
characteristic trends of specific residues and frequency of substitution.  
 












































Although the majority of the gene-specific trained PSAAP models did not perform as well 
for predicting pathogenicity in other genes-diseases, most still outperformed established 
algorithms.  As shown in Table 4.4, a majority of genes (13 out of 15) analyzed using the gene-
specific PSAAP trained algorithm had improved PPV as compared to other algorithms, with the 
overall PPV increasing 8.8% to 22.0%.   For example, the PSAAP model specific for SPRED1 
(93% PPV as seen in Table 4.3), when analyzed using established prediction algorithms yielded 
precision scores from 56% to 71%.  As mentioned above, the PSAAP model specific for RET 
kinase (94% PPV) underperformed for the ACVRL1 kinase (84% PPV), however, both still 
outperformed established algorithms, where on-line predictions for ACVRL1 only ranged from 
57% to 81% PPV.  Two exceptions to this trend were GALT and SMAD, in which MutPred and/or 
PMut scored slightly higher as shown bolded/underlined in Table 4.4.   
 
Figure 4.3 Disease specificity of pathogenic mutations demonstrated by plotting A) the 
RET proto-oncogene variants where 79% of pathogenic changes are cysteine [C] to 
another residue [X] and B) COL4A5 where 84% pathogenic changes are glycine [G] to 
another residue [X] again showing characteristic trends of specific residues and 
frequency of substitution that may be lost when diluting gene-specific data into genome 







Table 4.4 Gene-specific and all-gene algorithm PPV as compared to established algorithms. 
 
Gene            PSAAPa           All-geneb     SIFTc         PolyPhend            PMute         MutPredf          
ACVRL1  88        77  57  67  69        81 
AIP  91        71  71  73  80        79 
BTD  91        79  77  72  71        87 
CFTR  90        63  68  74  70        89 
COL4A5  88        82  58  74  62        73 
ENG  92        83  62  64  73        65 
GALT  86        77  66  65  58          87 
GJB2  87        77  69  74  67        83 
NF1  89        70  64  70  70        84 
PAH  89        80  59  76  77        84 
PMS2  88        63  64  74  74        72 
RET  94        84  78  54  72        84 
SLC22A5 90        82  74  76  53        82 
SMAD4  84        82  71  70  85        86 
SPRED1 93        86  71  65  56        71 
 
( avg 89.3        77.1  67.3  69.9  69.1       80.5 ) 
( min 84.0       63.0  57.0  54.0  53.0       65.0 ) 
( max 94.0       86.0  78.0  76.0  85.0       89.0 ) 
a Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained. 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, all-gene (n=20) trained. 
c Analyzed with default settings at http://sift.jcvi.org. 
d Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
e Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 





It is important to note that the all-gene trained Bayes predictor also compares favorably to 
established algorithms, with the average, minimum and maximum PPV for each predictor 
summarized in Table 4.4. For instance, although the gene-specific trained PSAAP model yielded 
the best PPV, the all-gene trained model outscores three of four established predictors, with 
MutPred being the exception.  This observation may highlight the importance of authoritative 
variant data and amino acid physicochemical properties being used to develop/train algorithms.  It 
also demonstrates that primary acid sequence only, when coupled with amino acid properties, 
can be successfully used to develop predictor algorithms. 
Finally, a minimum attribute set of amino acid properties seems specific to each gene-
disease, with overlap found among different genes using three feature selection methods ranging 
from 11% to 80% (Table 4.5).  Representative examples are shown in Figure 4.4.  Interestingly, 
the gene models with more shared amino acid attributes (GALT, 80%; NF1, 62%; SPRED1, 60%) 
also had the best generalizability. Of note, both SMAD4 and GALT did well using the established 
on-line prediction tools, where SMAD4 also had 58% overlap. Without considering the above 
mentioned 4 genes, the overlap ranged from only 11% to 37%.  Overlap for the all gene data set 
follows this same trend, showing only 38% overlap between the feature selection methods.   
 
Discussion 
The number of authoritative disease and locus specific gene variant collections in use for 
clinical diagnostics is rapidly growing.  These clinically-curated gene variant data sets, with 
reliable genotype-phenotype association, can readily be utilized for training and test set 
performance of machine classifiers.  The generalizability of classification rules across multiple 
genes and diseases may be strengthened as the number of curated disease variants continues to 
increase, although our analysis suggests that gene-specific approaches, with few exceptions, 
outperforms generic approaches.  Nonetheless, the recognition that the proposed classifier 
outperforms existing tools is important, given that it will take time for disease-specific curated 
genotype-phenotype databases to be developed and for some ultra-rare diseases such 








Table 4.5 Overlap of minimum set of amino acid properties describing disease association. 
 
  
  CfsSubset Relief-F SVM-RFE Overlap 
ACVRL1 7 39 49 7 
AIP 90 29 117 25 
BTD 41 20 39 8 
CFTR 19 161 139 12 
COL4A5 63 65 88 21 
ENG 13 82 59 9 
GALT 46 40 45 35 
GJB2 11 37 145 11 
NF1 28 20 39 18 
PAH 29 73 129 24 
PMS2 13 58 107 11 
RET 87 56 47 9 
SLC22A5 76 96 87 13 
SMAD4 63 65 88 42 
SPRED1 59 44 31 27 
All GENE 25 56 135 23 
      
















































Figure 4.4 Venn diagram showing overlap of amino acid properties to characterize benign  
and pathogenic gene variants using three feature selection methods (CfsSubset, Relief-
F, SVM-RFE).  Overlap for A) RET with only 14% shared attributes, B) GALT with a much 




For machine learning classifiers, amino acid attributes characteristic of substitution 
mutations for a given disease may be lost or diluted when combined with multiple genes and 
diseases.  A key distinguishing feature of this gene-specific classifier methodology is that 
algorithms are trained explicitly to curated monogenic disease outcomes.  Taking advantage of 
authoritative (clinically-curated) gene variant collections may avoid some inherent limitations of 
established prediction algorithms.  For example, since this methodology relies on primary 
sequence information only and uses calculated delta matrices of substituted amino acid 
properties, no homolog alignment or solved protein structure is necessary.  
This study included only gene variant collections with clearly documented disease 
association and known to the authors – and represents the largest collections to-date of clinically 
curated gene-disease results as used for diagnostic and gene test reporting purposes. Although 
correlation of genotype-phenotype offers therapeutic options that would otherwise remain hidden 
and may lead to disease specific mutation-guided management strategies, appropriate caution is 
justified when clinicians are asked to trust computational outcomes for determining patient care. 
[28] Continued interaction between clinicians and laboratorians to refine mutation-specific clinical 
classification is imperative to optimal patient care. 
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CONSENSUS: A FRAMEWORK FOR REPORTING  
UNCERTAIN GENE VARIANTS 
 
 






As electronic medical records incorporate genetic sequence information, gene variant 
classification is critical to inform clinicians on the most appropriate course of treatment.   
Proposed guidelines have recommended classification terminology and definitions for improving 
laboratory gene variant reporting.  A standardized framework however, does not yet exist for 
quantitative evaluation of disease association for novel gene variants in an objective manner.  
Gene-specific prediction was trained using clinically curated gene-disease data from the RET 
proto-oncogene.  This predictor output was implemented into a Consensus framework, including 
a weighted metric of existing and complementary prediction algorithms and calculated reference 
intervals from known disease outcomes. The Consensus model yields accurate evaluation of 
uncertain or novel gene variants against the backdrop of calculated reference intervals from 
known benign and pathogenic gene variants.  Where existing evidence for a gene variant is 
scarce, visualization of the Consensus output is also proposed for augmenting diagnostic 
decisions.  Accurate interpretation of gene testing is a key component in customizing patient 
therapy.  A reliable phenotype classification framework with a quantitative metric for evaluation of 
novel or uncertain gene variants can augment limited clinical information and assist in improving 




For appropriate and effective patient treatment, relevant clinical information should be 
available to the clinician on demand.  Accurate interpretation of gene test results, including 
phenotype association of gene variants, is an important component in customizing patient 
therapy.  Recent endeavors such as the NCBI Genetic Testing Registry, MutaDATABASE, 1000 
Genomes and the Human Variome Project draw attention to this growing interest in gene variant 
annotation and clinical interpretation in human disease.[1-4]  Ongoing efforts to catalog human 
genome variation for many years have led to authoritative repositories of gene variants with clear 
association to disease phenotype finally beginning to emerge.[5-8] 
Rapidly evolving technologies such as SNP chip genome wide association studies and 
next-generation sequencing has lowered the cost and increased the speed of genomic analysis 
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yielding much larger data sets.[9]  Currently, gene variants are being discovered at an 
unprecedented pace. One recent report found an average of 3 million variants per personal 
genome.[10]  Unfortunately, an ever-widening gap exists between this fast growing collection of 
genetic variation and practical clinical implementation due to a lack of understanding of the 
phenotypic consequences (if any) of any given variant.  Although the number of genetic testing 
laboratories has remained around 600 over the past several years, recent data shows that clinical 
testing is currently available for well over 2200 different genes or genetic conditions 
(www.genetests.org).  As medical records increasingly incorporate genetic test information, 
improved decision support approaches are needed to provide clinicians with the preferred course 
of treatment.[11]  Furthermore, for decision support rules to be of value, the clinical relevance of 
laboratory information must be well understood.[12] 
Updated recommendations have been proposed from the American College of Medical 
Geneticists (ACMG) on reporting and classification of sequence variants, including approaches to 
help determine the clinical significance of variants of uncertain significance.[13]  These guidelines 
delineate six interpretative categories of gene sequence variation, with defined classifications 
outlined and the hope of a unified standard terminology in gene test reporting.   For improving 
interpretation of unclassified genetic variants, definitions and terminology has also been 
recommended by the International Agency for Research on Cancer (IARC), part of the World 
Health Organization).[14]  
Despite these recommendations, however, for genetic laboratories to unify and 
standardize terminology and classification of gene variant test reporting, various terms such as 
deleterious, mutation, pathogenic or causative of disease are still being used.[15]  In a similar 
vein, test results such as indeterminate, unknown, uncertain, unclassified and undetermined 
make it difficult to interpret the significance of a gene test result. Further compounding this issue, 
word modifiers such as likely, suspected, predicted and mild, moderate or severe sometimes also 
accompany variant classification.  Of this environment, one recent study perceptively noted, “The 
outcome of this inconsistency for clinicians and patients in such cases is uninformative; unhelpful 
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at best and, at worst, open to misinterpretation.”[16]  In this light, the prevailing question becomes 
how to best help clinicians faced with decisions around gene variants of uncertain significance. 
A brief review of the literature indicates that gene test reports of variants of uncertain 
significance range widely.  One laboratory site reported that from 30% to 50% of sequence 
changes reported for BRCA1 and BRCA2, respectively, were reported as variants of uncertain 
significance.[17]  Similarly, analysis of a second laboratory revealed that a physician who orders 
BRCA1 and BRCA2 testing had an equal likelihood (13%) of receiving a uncertain variant result 
as seeing a test report containing a known pathogenic mutation.[18]  More recent data indicates 
that identification of variants of uncertain significance has continued to decline to approximately 
5% of BRCA tests performed – a testament to the importance of maintaining and updating variant 
databases.[19]   
Another well known example is hereditary nonpolyposis colorectal cancer (HNPCC) 
syndrome, where according to the U.S. Preventive Services Task Force and others, a clinician 
may expect some 13% to 31% of tests reports to say mutation of unknown significance (uncertain 
variant).[20, 21]  An uncertain variant indicates that the risk of cancer is not fully defined and 
patient treatment is then based on personal and family history of cancer.  Clinicians may be 
further frustrated when the chance of receiving a test report containing an uncertain variant is 
even higher for individuals from under-represented ethnic groups due to insufficient data on 
common polymorphisms from that population.[22]  Additionally, newly identified variants from 
known genes present a greater challenge for interpretation of sequence-based results because 
they lack traditional confirming evidence of disease association.[23]  
Clinician frustration and obstacles to wide adoption of proposed guidelines may be two-
fold.  First, the lack of any quantitative metric or standardized scale for evaluation of novel or 
uncertain gene variants make each difficult test result interpretation subjective to location and 
expertise at hand.  A second and closely related challenge is the lack of an objective and 
standardized framework or context to make that metric meaningful.  This quantitative metric and 
framework for evaluation become especially critical for interpretation of novel and uncertain gene 
variants where by definition, traditional confirming evidence such as family history, pedigree trios 
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or sib pairs, confirming literature reports, bench assay biochemical evidence or colleague 
consensus of disease association is lacking. 
With analogy to conventional laboratory testing, a given analysis will have well 
characterized instrument and assay performance, as well as context for appropriate interpretation 
such as age and gender specific reference intervals.  This allows the laboratory to then 
standardize with relative ease what is "normal" or "abnormal."   
Medical geneticists rely on patient history, family segregation, literature review and 
trusted colleagues to stay informed of the phenotypic consequences of a given gene variant.  In 
addition, well established computer prediction tools are also employed.[13, 24]  Is there a 
supporting computational method that can serve to replicate this same mental process of 
gathering evidence from complementary sources, assessing agreement of the evidence and 
summarizing this evidence into a clinical context for interpretation of the gene variant finding? 
In an effort to increase the transparency of providing gene variant evidence in test 
reporting to the clinical setting, we here propose a practical implementation of our recently 
reported Primary Sequence Amino Acid Properties (PSAAP) gene-specific predictor into a 
standardized framework.  This combined model of complementary predictors and calculated gene 
variant reference intervals for a given disease we here term Consensus.   Examples of 
Consensus visualization are also explored for augmenting diagnostic decision making. 
 
Methods 
Several clinically curated disease sets of gene variants with known pathogenicity are 
publicly available at http://www.arup.utah.edu/database/.  Each database relies on both medical 
and molecular expertise, and uniquely displays mutation and clinical information together.  All 
sequence variants are verified for genomic position within a given reference gene.  Variants are 
named following standard Human Genome Organization (HUGO) nomenclature. Archived non-
synonymous substitution variants were accessed from the RET proto-oncogene database in 
January 2011.[25]   
Various established prediction algorithms were chosen with orthogonal and 
complementary methodologies such as amino acid substitution penalties, structural disruption, 
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sequence homology (ortholog conservation) and neural nets. Mutation prediction was then 
performed for known benign (n=46), known pathogenic (n=51) and uncertain variants (n=45) 
using our gene-specific PSAAP algorithm, and established algorithms MutPred[26], PMUT[27], 
PolyPhen[28] and SIFT[29] as previously described.[30, 31]  Prediction analysis was performed 
during January and February 2011 using the respective default settings for each algorithm. 
Descriptive statistics (mean, median, standard deviation, minimum and maximum) were 
calculated for the numerical output from all five predictor algorithms. Spearman correlation 
coefficients were then determined to evaluate correlation between predictors.  Principle 
components were calculated using factor analysis to determine independence of the five 
predictors.  To compensate for lack of independence between variables, the resulting analysis of 
variance was used for linear transformation into a weighted sum of predictor values.   The 
weighted average of the five predictor scores was then calculated as the “Consensus” score.   All 
calculations were performed using SAS software, Version 9.1 of the SAS System Copyright © 
2002-2003 SAS Institute Inc, Cary, NC, USA.  
Next, with analogy to calculating analyte reference intervals for age or gender in 
traditional laboratory testing, a “reference range” of Consensus scores for RET gene variants with 
known disease outcome was calculated using EP Evaluator 8 (Data Innovations, South 
Burlington, VT).  A nonparametric reference interval was used for benign (n=46) and pathogenic 
(n=51) with 95% confidence intervals (CI) for the lower and upper bounds.  The confidence ratio 
of the reference interval was also calculated. Due to the reciprocal nature of the SIFT score 
(where a lower prediction value corresponds to more “pathogenic”), 1-SIFT was used.  All 
predictor scores were normalized to a scale of 0 to 100. 
Finally, in order to confirm performance of the Consensus framework, we retrospectively 
removed seven RET gene variants with known disease association (2 benign, 5 pathogenic) from 
training and test sets and repeated analysis using the proposed model framework.  Disease 
outcome predictions and Consensus scoring was evaluated for each of these variants. 
Appropriate graphical summary of diagnostic information, including predictive algorithms 
are key for visualization and interpretation of any results generated.[32]  We have loosely based 
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the Consensus display on output from representative algorithms such as Scolioscore 
(http://www.axialbiotech.com) and FibroTest (http://www.biopredictive.com).  Finally, the use of 
radar (radial) plots is well documented and serves to preserve contribution of each predictor in 
the weighted Consensus sum.[33, 34] 
 
Results 
Prediction results (numerical output) from the five algorithms were obtained for RET gene 
variants with known disease association of benign (Table 5.1) and pathogenic (Table 5.2).  
Predictor results for RET gene variants with no reported disease association (uncertain) are 
summarized in Table 5.3.  Results of correlation between predictors and significance of 
correlation are summarized in Table 5.4.  Substantial correlation was seen in at least three of the 
five predictors (MutPred, PSAAP, and PMUT).  This significant correlation between variables 
indicates that a simple linear sum of predictors could not be used to combine the prediction 
scores.  A weighted predictor sum (Consensus) required linear transformation of predictor outputs 
as determined by factors analysis. 
Factor analysis was performed using principal components to determine weights of 
association between the five different predictors. More specifically, a set of eigenvectors was 
applied to weight each predictor accordingly by eigenvalues from principal components, with 
>80% cumulative variance explained reached using only the first three eigenvalues.  Factors 
analysis and percent variance explained is detailed in Figure 5.1.  PRINCOMP results and 
eigenvalues are summarized in Table 5.5.   
A working example of the Consensus score for both a known benign and known 
pathogenic RET gene variant is detailed in Table 5.6, where each predictor sum is weighed and 
scaled to 100.  Using this same method to sum each of the 5 predictors for each gene variant, we 
then computed reference range metrics for benign and pathogenic variants for the RET proto-
oncogene.  Benign variants ranged from 85 to 243, while pathogenic variants ranged from 305 to 
462.    Confidence ratios for the calculated reference intervals were 0.09 and 0.16 respectively.  
The RET gene variant Consensus reference intervals are summarized in Table 5.7.  Scatter plot 
distribution of the RET Consensus scores for benign and pathogenic is displayed in Figure 5.2A.  
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Table 5.1 Five predictor results for benign RET gene variants. 
 
 
Varianta PSAPPb MutPredc PMUTd  PolyPhene SIFTf 
A432E  0.12  0.00  0.63  0.79  1.00 
C609W  0.24  0.91  0.89  0.99  0.50 
D489N  0.97  0.00  0.24  1.00  0.20 
E251K  0.16  0.00  0.63  1.00  0.64 
E623K  0.14  0.51  0.83  1.00  0.80 
E762Q  0.23  0.68  0.04  1.00  0.09 
F1112Y  0.23  0.00  0.03  1.00  0.37 
F174S  0.19  0.00  0.11  1.00  0.09 
F393L  0.17  0.00  0.39  1.00  0.20 
G691S  0.26  0.20  0.66  1.00  0.66 
G894S  0.58  0.99  0.77  1.00  0.50 
G93S  0.11  0.00  0.51  1.00  0.00 
L1061P  0.09  0.75  0.65  1.00  0.10 
L40P  0.19  0.00  0.08  1.00  0.00 
M1064T  0.14  0.58  0.70  0.75  0.13 
N359K  0.16  0.00  0.64  1.00  0.25 
N394H  0.25  0.00  0.40  1.00  0.01 
N394K  0.12  0.00  0.52  1.00  0.01 
P1039Q  0.07  0.72  0.66  0.98  0.30 
P1049L  0.09  0.57  0.84  1.00  0.20 
P1067S  0.13  0.29  0.79  1.00  0.21 
P198T  0.21  0.00  0.62  1.00  0.01 
P20L  0.23  0.00  0.27  1.00  0.16 
P399L  0.03  0.00  0.72  1.00  0.03 
P64L  0.16  0.00  0.17  1.00  0.01 
R114H  0.18  0.00  0.61  1.00  0.16 
R163Q  0.03  0.00  0.53  0.00  0.25 
R180P  0.25  0.00  0.68  1.00  0.24 
R231H  0.10  0.00  0.48  0.98  0.56 
R287Q  0.12  0.00  0.47  0.75  0.02 
R313Q  0.25  0.00  0.57  0.37  0.03 
R330Q  0.10  0.00  0.57  0.96  0.44 
R360W  0.17  0.00  0.94  0.65  0.00 
R475Q  0.08  0.00  0.71  0.79  0.29 
R67H  0.15  0.00  0.25  1.00  0.55 
R77C  0.11  0.00  0.26  1.00  0.06 
R972G  0.52  0.91  0.71  1.00  0.10 
R982C  0.16  0.89  0.65  1.00  0.70 
S493E  0.07  0.00  0.66  1.00  0.97 
S690P  0.62  0.53  0.46  1.00  0.14 
S836Y  0.13  0.46  0.78  1.00  0.77 
S922Y  0.61  0.92  0.77  0.82  0.80 
T278N  0.12  0.00  0.22  1.00  0.29 
V145G  0.12  0.00  0.31  1.00  0.00 
V376A  0.07  0.13  0.19  0.04  0.60 
Y806C  0.67  0.90  0.91  0.43  0.81 
a RET_HUMAN (UniProt #P07949) used as reference amino acid sequence. 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained. 
c Analyzed with default settings at http://mutdb.org/mutpred. 
d Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
e Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 




Table  5.2 Five predictor results for pathogenic RET gene variants. 
 
 
Varianta PSAPPb MutPredc PMUTd  PolyPhene SIFTf 
A640G  0.82  0.58  0.13  0.86  0.34 
A883F  0.95  0.91  0.64  0.99  0.00 
C515S  0.91  0.00  0.83  0.02  0.19 
C609F  0.77  0.79  0.84  0.99  0.00 
C609G  0.94  0.89  0.88  0.99  0.00 
C609R  0.91  0.87  0.93  0.01  0.00 
C609S  0.87  0.90  0.61  0.97  0.00 
C609Y  0.85  0.90  0.98  0.97  0.00 
C611F  0.92  0.93  0.73  1.00  0.00 
C611G  0.86  0.92  0.80  1.00  0.00 
C611R  0.77  0.92  0.86  1.00  0.00 
C611S  0.77  0.90  0.42  0.00  0.00 
C611W  0.78  0.94  0.80  0.31  0.00 
C611Y  0.74  0.96  0.96  0.29  0.00 
C618F  0.79  0.90  0.86  0.20  0.58 
C618G  0.88  0.88  0.89  0.97  0.41 
C618R  0.97  0.85  0.94  0.99  0.28 
C618S  0.97  0.85  0.80  0.94  0.50 
C618W  0.89  0.77  0.90  1.00  0.13 
C618Y  0.75  0.89  0.98  0.98  0.84 
C620F  0.81  0.86  0.81  1.00  0.23 
C620G  0.87  0.83  0.70  1.00  0.46 
C620R  0.79  0.75  0.88  1.00  0.69 
C620S  0.91  0.81  0.70  1.00  0.74 
C620W  0.85  0.84  0.81  0.00  0.06 
C620Y  0.80  0.84  0.96  0.99  0.00 
C630F  0.78  0.76  0.61  0.00  0.06 
C630R  0.83  0.70  0.79  1.00  0.84 
C630S  0.90  0.73  0.42  1.00  0.34 
C630Y  0.87  0.75  0.94  1.00  1.00 
C634F  0.85  0.83  0.75  1.00  0.04 
C634G  0.82  0.78  0.84  1.00  0.02 
C634L  0.77  0.69  0.39  1.00  0.80 
C634R  0.85  0.79  0.88  1.00  0.02 
C634S  0.87  0.82  0.43  1.00  0.04 
C634W  0.89  0.83  0.81  1.00  0.01 
C634Y  0.90  0.81  0.97  1.00  0.13 
D631Y  0.87  0.69  0.68  1.00  0.02 
E768D  0.47  0.56  0.16  1.00  0.13 
G533C  0.78  0.00  0.79  1.00  0.00 
K666E  0.85  0.51  0.24  1.00  0.31 
L790F  0.97  0.80  0.12  1.00  0.01 
M918T  0.41  0.54  0.79  1.00  0.00 
R844L  0.39  0.84  0.83  1.00  0.10 
S649L  0.87  0.66  0.46  0.99  0.65 
S891A  0.78  0.67  0.08  1.00  0.31 
S922F  0.42  0.89  0.68  1.00  0.00 
T946M  0.89  0.76  0.78  0.89  0.60 
V292M  0.95  0.50  0.96  1.00  0.14 
V804L  0.84  0.73  0.17  1.00  0.03 
V804M  0.90  0.77  0.11  1.00  0.09 
a RET_HUMAN (UniProt #P07949) used as reference amino acid sequence. 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained. 
c Analyzed with default settings at http://mutdb.org/mutpred. 
d Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
e Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
f Analyzed with default settings at http://sift.jcvi.org. 
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Table 5.3 Five predictor results for uncertain RET gene variants. 
 
 
Varianta PSAPPb MutPredc PMUTd  PolyPhene SIFTf 
G321R  0.41  N/A  0.74  0.00  0.50 
A510V  0.11  N/A  0.25  0.00  0.08 
E511K  0.17  N/A  0.78  0.01  0.24 
C531R  0.60  N/A  0.83  1.00  0.28 
G533S  0.40  N/A  0.14  0.99  0.00 
R600Q  1.00  N/A  0.41  0.00  0.27 
K603Q  0.40  N/A  0.45  0.00  0.47 
Y606C  0.38  0.54  0.91  0.90  0.23 
C609S  0.92  0.90  0.61  1.00  0.00 
C611S  0.77  0.90  0.42  1.00  0.00 
C630S  0.79  0.73  0.42  1.00  0.34 
D631N  0.89  0.61  0.18  0.05  0.19 
D631A  0.53  0.65  0.75  0.98  0.01 
D631G  0.31  0.62  0.51  0.93  0.02 
D631V  0.77  0.60  0.64  0.98  0.00 
D631E  0.14  0.39  0.24  0.85  0.07 
E632K  0.40  0.63  0.16  0.13  0.19 
R635G  0.41  0.71  0.76  1.00  0.10 
A640G  0.22  0.58  0.13  0.00  0.50 
A641S  0.26  0.59  0.02  0.29  0.09 
V648I  0.30  0.58  0.10  0.00  0.75 
S649L  0.46  0.66  0.46  1.00  0.32 
H665Q  0.30  0.52  0.58  1.00  0.57 
K666N  0.07  0.49  0.16  0.99  0.33 
R770Q  1.00  0.44  0.49  1.00  0.08 
N777S  0.27  0.65  0.35  0.28  0.64 
V778I  0.30  0.52  0.02  0.00  0.02 
Y791N  0.78  0.89  0.86  0.99  0.00 
E805K  0.68  0.88  0.66  1.00  0.00 
E818K  0.40  0.51  0.16  0.38  0.19 
S819I  0.73  0.77  0.48  1.00  0.00 
R833C  0.70  0.59  0.91  1.00  0.00 
P841L  0.54  0.60  0.81  1.00  0.67 
E843D  0.81  0.70  0.04  0.00  0.12 
R844W  0.84  0.77  0.99  1.00  0.00 
R844Q  1.00  0.64  0.65  1.00  0.06 
R844L  0.83  0.84  0.83  1.00  0.02 
M848T  0.62  0.67  0.80  1.00  0.08 
I852M  0.84  0.74  0.07  0.99  0.04 
L881V  0.60  0.81  0.11  0.96  0.00 
R886W  0.74  0.78  0.98  1.00  0.00 
S904C  0.82  0.72  0.61  0.98  0.01 
S904F  0.75  0.65  0.83  1.00  0.00 
K907E  0.60  0.71  0.27  0.99  0.00 
K907M  0.58  0.64  0.30  0.99  0.00 
R912Q  1.00  0.94  0.55  1.00  0.00 
a RET_HUMAN (UniProt #P07949) used as reference amino acid sequence. 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained. 
c Analyzed with default settings at http://mutdb.org/mutpred. 
d Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
e Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 




Table 5.4 Descriptive statistics for RET gene variants with known disease association (including 





Variable N Mean  Std Dev Median            Minimum          Maximum 
 
MutPred 97 0.5072  0.3881  0.6900  0.0000  0.9900 
 
PMut  97 0.6070  0.2729  0.6798  0.0342  0.9809 
Poly  97 0.8537  0.3112  0.9990  0.0000  1.0000 
PSAAP  97 0.5336  0.3446  0.6700  0.0300  0.9700 
SIFT  97 0.2401  0.2927  0.1300  0.0000  1.0000 
 
Spearman Correlation Coefficients 
 
 
  MutPred PMUT  PolyPhen PSAAP 
 
MutPred **    
PMut  0.541  **   
Poly  -0.204  -0.289  **  
PSAAP  0.562  0.250  -0.134  ** 
SIFT  -0.296  -0.118  0.001  -0.118 
 
P-value of correlation 
 
 
MutPred PMUT  PolyPhen PSAAP 
 
**    
<.0001  **   
0.0452  0.0041  **  
<.0001  0.0134  0.1898  ** 




Further demonstrating the utility of a reference interval metric for gene variants, the 
distribution of Consensus scores for prediction of RET uncertain gene variants shows 
approximate groupings into reference interval ranges as plotted in Figure 5.2B.   
In combination, the overall Consensus score may augment the rare instance that a gene-
specific prediction does not outperform the existing tools.  This advantage of Consensus over a 
single predictor was seen by removing seven RET gene variants with known disease association 
where originally they were classified as variants of uncertain significance.  After excluding these 
seven variants from the gene-specific training set, analysis using the Consensus framework was 
repeated.  Due to the lack of a representative variant in the training data, PSAAP only called 
disease association correctly in five out of seven variants. However, in combination, the 
Consensus score correctly predicted the 6th variant.  Closer inspection showed the remaining 7th 
variant was a nucleotide level “silent” polymorphism (no amino acid change), which could have 
been recognized by spice effect prediction software. 
Finally, one common graphing display technique to preserve contribution of each variable 
(predictor) is the use of radial plots (also known as radar or spider plots).  RET Consensus 
scoring results for the pathogenic variant C609Y and benign variant V376A are shown using 
radar plots in Figure 5.3.   For augmenting clinical decision making, a more comprehensive 
display for Consensus scoring is shown in Figure 5.4 which incorporates algorithm output, 
predictor calls, weighted sum and colormetric scale.    
 
Discussion 
Currently, there is no widely accepted computational predictor in clinical use for 
evaluating uncertain gene variants.  Furthermore, a lack of standardized framework and 
quantitative metric for evaluation of disease association of novel and uncertain variants remains 
an obstacle to widespread implementation of proposed guidelines and definitions of gene test 
reporting.  The analogy of conventional laboratory analyte testing with established cutoffs and 
reference intervals may serve as a pattern for gene variant testing.  In this regard, we have 
developed a standardized framework and metric for evaluation of uncertain gene variants, with 






Figure 5.1 Analysis of variance explained as determined by using principal components.  
A) Scree plot of descending eigenvalues displaying the five principal components 
corresponding to the combined predictor algorithms.  B) Percent variance explained 












Table 5.5 Principal components and eigenvalues of predictor scores from RET gene variants with 
known disease association. 
 
 
Eigenvalues of the Correlation Matrix 
 
 
Eigenvalue  Difference  Proportion  Cumulative 
  
1  2.03136792   0.97261793   0.4063    0.4063 
2  1.05874999   0.11844368   0.2117    0.6180 
3  0.94030630   0.23882133   0.1881    0.8061 
4  0.70148497   0.43339416   0.1403    0.9464 





            Prin1  Prin2  Prin3  Prin4  Prin5  
  
MutPred  0.622645  0.141730  0.219197  -.017230  -.737483 
PMut   0.464901  0.357804  -.064845  0.754559  0.286843 
Poly   -.273897  0.401935  0.773679  0.400519  0.066595 
PSAAP  0.563184  0.245172  0.247588  -.440005  0.606474 







the evidence and decision making is transparent to clinician so they can use this in consultation 
with the patient to make treatment decisions.   
It is likely that providing this type of information will impact clinical decision making. While 
critics may argue that relying solely on a computational framework might ‘mislead’ clinicians in 
that we don’t have the best evidence (i.e., a true known genotype-phenotype correlation), the 
reality is that clinicians still have to make treatment decisions based on any “uncertain 
significance” result.  We propose that increasing the transparency of gene test evidence and 
interpretation would only help the clinician as compared to a situation where results that are on 
the border of benign and those on the border of pathogenic are treated the same.  As Consensus 
is implemented into a laboratory setting, coordination with a clinical site to test how clinicians use 
the information would be an important and necessary follow-up study. 
The lack of a widely accepted standard for computational predictors in a clinical setting 
remains a serious obstacle in the diagnostic utility of these algorithms.  Gene-specific prediction 
algorithms been shown to be an improvement over existing generalized prediction tools, where a 
larger data set “n” for training algorithms may not compensate for lower quality of phenotype 
information.  Examples of this gene-disease specific focus using computational prediction have 
recently been shown for hypertrophic cardiomyopathy and in the RET proto-oncogene.[31, 35]  
We have recently summarized similar efforts in gene-specific prediction for an authoritative 20 
gene-disease data set showing similar improved prediction (submitted for publication).  Focusing 
prediction algorithms on authoritative and specific gene-disease settings may aid to bridge this 
acceptance gap and shed additional light on clinical interpretation of uncertain gene variants.  
With ongoing efforts to amass gene variation in human disease, newly emerging “authoritative” or 
“diagnostic grade” clinically curated gene variant archives should be leveraged for training and 
testing machine learning classification tools.   
Another key issue is that disease classification of gene variants evolves over time as new 
knowledge becomes available.  We note that this is a problem whether one uses this proposed 
framework or the status quo system for dealing with gene test results of uncertain significance.  
At present, there is no way to communicate new variant knowledge effectively between gene test  
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Table 5.6 Example of Consensus weighted sum. 
 
 
Predictor   Prin1   Prin2   Prin3 
 
PSAAP    0.56   0.25   0.25 
 
MutPred    0.62   0.14   0.22 
 
PMUT    0.46   0.36   -0.06 
 
PolyPhen   -0.27   0.40   0.77 
 
one_minus_SIFT   0.06   0.79   -0.54 
 
 
Varianta  PSAPPb  MutPredc PMUTd  PolyPhene SIFTf 
 
Pathogenic 
C609Y   0.85  0.90  0.98  0.97  0.00 
 
Vector1 =    0.85*0.56     +    0.90*0.62     +  0.98*0.46     +  0.97*-0.27     +  (1-0.00)*0.06  = 1.283 
    
Vector2 =    0.85*0.25     +    0.90*0.14     +  0.98*0.36     +  0.97*0.40      +  (1-0.00)*0.79 = 1.869 
 
Vector3 =    0.85*0.25     +    0.90*0.22     +  0.98*-0.06    +  0.97*0.77      +   (1-0.00)*-0.54 = 0.559 
 
               Weighted sum (x 100) = 371.1 
Benign 
V376A  0.07  0.00  0.19  1.00  0.60 
 
Vector1 =    0.07*0.56     +    0.00*0.62     +  0.19*0.46     +  1.00*-0.27     +  (1-0.60)*0.06  = -0.119 
 
Vector2 =    0.07*0.25     +    0.00*0.14     +  0.19*0.36     +  1.00*0.40      +  (1-0.60)*0.79 =  0.786 
 
Vector3 =    0.07*0.25     +    0.00*0.22     +  0.19*-0.06    +  1.00*0.77      +  (1-0.60)*-0.54 =  0.560 
 
               Weighted sum (x 100) = 146.5 
a RET_HUMAN (UniProt #P07949) used as reference amino acid sequence. 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained. 
c Analyzed with default settings at http://mutdb.org/mutpred. 
d Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
e Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 




Table 5.7 Consensus score reference intervals for RET gene variants. 
 
Disease   Lower Limit   Upper Limit                 Confidence 
Outcome N value 95% CI   value 95% CI                 Ratio 
 
Benign  46 85 <76 to 98  243 231 to >255        >0.09 
 






























Figure 5.2 Scatter plot visualization of Consensus scores for RET gene variants including 
A) known benign, known pathogenic disease association and B) RET gene variants of 
uncertain significance, showing the utility of reference interval metrics for predicted 
benign and predicted pathogenic. 
RET Consensus Scores

















































Figure 5.3 Using radar plots for Consensus scoring preserves the contribution of each 
predictor to the total sum.  A) Consensus score plot of 470 (85, 90, 98, 97, 100) for the 
pathogenic gene variant C609Y.  B) Consensus output of 83 (7, 13, 19, 4, 40) for a 















































Predictor Raw Call Consensus Weights
PSAAP 0.26 benign 27.4 PSAAP(0.563+0.245+0.247)*100 
MutPred 0.20 benign 19.1 MutPred(0.622+0.141+0.219)*100 
PMUT 0.66 neutral 50.1 PMUT(0.464+0.357-0.064)*100 
PolyPhen 0.00 benign 0.0 PolyPhen(-0.237+0.401+0.77)*100 
SIFT 0.66 tolerated 10.9 1-SIFT(0.063+0.793-0.536)*100 
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RET – C634R 
Predictor Raw Call Consensus Weights
PSAAP 0.85 pathogenic  89.7 PSAAP(0.563+0.245+0.247)*100 
MutPred 0.79 pathogenic  77.7 MutPred(0.622+0.141+0.219)*100 
PMUT 0.88 pathological  78.1 PMUT(0.464+0.357-0.064)*100 
PolyPhen 1.00 prob damaging 90.1 PolyPhen(-0.237+0.401+0.77)*100 
SIFT 0.02 af fects function 31.4 1-SIFT(0.063+0.793-0.536)*100 
367
 
Figure 5.4 Visualization of the 5 predictor Consensus model including algorithm output, 
predictor calls, weighting sum and colormetric scale for A) pathogenic gene variant 





laboratories and clinicians.  Thus, a standardized framework would allow for consistent and 
objective data provenance for longitudinal tracking of both variants and patient results, where 
notifying interested parties in updated variant classification and disease association would be 
more feasible.  We also note that developing this framework now using monogenic diseases may 
allow increased understanding that could eventually be applied to multi-gene panel or whole 
genome approaches. 
For scenarios lacking conventional gene variant evidence, the five specific predictors 
used for Consensus were carefully chosen due to the varied computational approach of each 
algorithm.  Analysis of variance shows the majority of the weighted average stems from three of 
the five predictors (PSAAP, MutPred and PMUT).  This may be indicative of the unique and 
varied approach of the three predictors.  SIFT and PolyPhen were also included in the 
Consensus score for a “wisdom of the crowd” historical context due to the fact that many 
laboratories may already have these prediction algorithms in use.   
One limitation of this methodology is the fact that although several popular gene variants 
collections are ongoing (i.e., dbSNP has recently passed the 12 million unique human gene 
variant milestone), a relatively small number of clinically-curated and authoritative gene-disease 
collections exist as used for diagnostic purposes.  Fortunately, this number will continue to 
expand over time, not diminish, as gene-disease associations are better understood and 
personalized patient treatments advance.  Another limitation is that mutation archives often have 
an unbalanced proportion of disease causing gene variants, and appropriate machine learning 
techniques must be used to compensate for uneven training and test data.  Perhaps the most 
important limitation to acknowledge is how can we know whether a prediction for a gene variant 
of uncertain significance is truly correct?  The honest response is likely “we can’t.”   While only 
the passage of time may confirm the accuracy of a computational prediction, an important point 
not to dismiss is – would this approach (or similar) likely lead to better or worse decision making 
by providers?  There may be analogous situations in other existing laboratory tests, where for 
example, anatomic pathology may yield some ideas that clinicians rely on for decision making. 
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The pathology report contains all information, not just the “interpretation.” This would imply that 
more information (not less) is appropriate for clinician decision making.[16, 36]   
There may be some perceived liability for a laboratory that would report using this 
augmented methodology as compared to existing gene test reporting approaches. Although 
correlation of genotype-phenotype offers therapeutic options that would otherwise remain hidden 
and may lead to disease specific mutation-guided management strategies, appropriate caution is 
justified when clinicians are asked to trust computational outcomes for determining patient 
care.[37]  On the other hand, when results are reported to clinicians and patients as variants of 
unknown significance, it may take years for sufficient molecular or family evidence to be 
confirmed for the laboratory to make a final determination. Interpretation of gene test results that 
are unclear or uncertain may be troubling for patients, and must have some effect (good or bad) 
on how clinicians manage these patients.[38]  Transparent communication of summarized gene 
variant evidence and continued interaction between clinicians and laboratorians to refine 
mutation-specific clinical classification is imperative to optimal patient care.  Recent examples of 
this importance have been detailed in newborn screening and case studies from cardiovascular 
genetics.[39, 40]   
Gene variants are currently being identified at a tremendous pace.  While many of these 
sequence changes may be considered as normal population allele variants, some percentage will 
certainly have disease association.  Gene variants may be best leveraged for clinical utility by 
focusing on specific gene-disease areas.  In concert, clinicians and diagnostic laboratories are 
the best source of authoritative gene variant annotation.  Ranking agreement through the use of a 
weighted Consensus metric of predicted pathogenicity across several complementary algorithms 
may provide a level of clinical confidence in computational classifiers.  
A proposed visual for augmenting the gene test report of an uncertain gene variant using 
known benign and pathogenic gene variants mapped onto a schematic of the RET protein is 
displayed in Figure 5.5.  The protein diagram image is courtesy of the Human Protein Reference 
Database (HPRD.org).  The variant being evaluated is denoted by “X” along the length of the 
protein and Consensus scoring of the variant is detailed using both the reference intervals with 
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colormetric scale and radial chart to show contribution of each predictor.  Ongoing efforts include 
expanding the Consensus scoring framework and phenotype reference intervals to additional 
genes and diseases.  Future efforts will be necessary to incorporate algorithm layers for 
nucleotide level prediction and functional protein motifs.   
Figure 5.5 Proposed visualization of Consensus scoring using known gene variants 
plotted on the RET_HUMAN (UniProt #P07949) protein (image courtesy of HPRD.org) 
and algorithm output and spider plots to summarize predictor evidence for A) pathogenic 
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Rapidly evolving technologies such as DNA chip arrays and next-generation sequencing 
continue to decrease costs for genomic analysis yet yield much larger data sets.[1]  As such, 
gene sequence variation in humans is being discovered at an unprecedented pace.  A widening 
gap exists between this growing collection of genetic variation and meaningful clinical 
implementation due to a lack of clear phenotypic consequences (if any) of a given gene variant. 
As medical records increasingly incorporate genetic test information, improved decision support 
approaches are needed to augment gene variant interpretation to provide clinicians with the 
preferred course of treatment.[2]  Furthermore, for laboratory decision support rules to be of 
greatest value, the clinical relevance of laboratory information must be well understood and prior 
to clinical decision making for patient treatment.[3-5]   
Guidelines have been proposed from the American College of Medical Geneticists 
(ACMG) on reporting and classification of sequence variants have recently been published.[6]  
Similar recommendations by the International Agency for Research on Cancer (IARC) have also 
been published.[7] These recent efforts suggest definitions and approaches to help determine 
gene variant classification, including the clinical significance of variants of uncertain significance.  
Despite these recommendations however, genetic laboratories in large part, have failed to unify 
and standardize terminology and classification of gene variant test reporting.  A related challenge 
is the lack of an objective disease context or decision support framework to make that metric 
useful.  This quantitative metric and framework for evaluation are especially critical for 
interpretation of novel and uncertain gene variants where there is a lack of confirming evidence 
such as family history, literature reports or biochemical assays for the laboratory to assemble. 
Further, this absence of decision support framework and quantitative metric for evaluation of 
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disease association of novel and uncertain variants remains an obstacle to widespread 
implementation of proposed guidelines for gene test reporting.  Currently, there is no widely 
accepted computational predictor in clinical use for evaluating uncertain gene variants.   
As enormous amounts of genome variation become publically available, data sets for 
algorithm training typically number into the tens of 1000’s or more. Generalized prediction 
algorithms are largely homolog or structural based, yet characteristic mutation properties of a 
given disease and gene may be lost when diluted into genomewide data sets.  Importantly, there 
are a growing number of authoritative and clinically curated gene variants collections being 
assembled for diagnostic purposes.  Gene variant phenotype information may be best leveraged 
for clinical utility by focusing on specific gene-disease areas.  
Algorithm agreement in a clinical setting may be just as important for “benign” as it might 
be for “pathogenic.”  Ranking agreement of predicted phenotype severity across several 
complementary algorithms may provide an additional level of clinical confidence in computational 
classifiers.  At a minimum, all-in-agreement “predicted pathogenic” gene variants warrant closer 
investigation by traditional and molecular techniques.  More importantly, agreement between 
several predictors may provide research priority for novel and uncertain gene variants. 
 
Contributions 
 An accurate gene-specific Primary Sequence Amino Acid Properties (PSAAP) prediction 
algorithm was developed using a combination primary amino acid sequence, amino acid 
properties as descriptors and Naïve Bayes classification based on authoritative training sets.  
This algorithm was implemented with a weighted average of complementary prediction tools into 
a Consensus framework of calculated reference intervals of specific disease outcomes for 
improving laboratory decision making in regards to uncertain gene variants.  These efforts have 
led to the development of several key contributions to not only bioinformatics but also medical 
genetics and laboratory medicine.   Specific contributions include: 
1. Many established prediction tools for evaluating pathogenicity of gene variants rely on 
multiple alignment of sequence conservation across many species and/or solved protein 
structure to assess structural disruption.  Leveraging authoritative gene-variant 
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collections with high quality genotype-phenotype disease outcomes allowed the 
development of gene-specific prediction algorithms with improved accuracy as compared 
to previous prediction tools.  Importantly, limitations of sequence homology and known 
protein structure were not required for the successful use of PSAAP predictions.  
2. A related contribution was the important observation that characteristic biochemical 
and/or structural changes specific to one disease may be lost or diluted when combined 
with large genome-wide data sets for algorithm development.  This suggests that 
machine learning training sets using a very large “n”, as common in many established 
prediction algorithms, may not always compensate for lower quality data.  Stated 
conversely, characteristic trends of specific amino acid residues and frequency of 
substitution as found in smaller clinically-curated gene variant disease collections may 
add power, specificity and accuracy to the prediction tool. 
3. Assembly of authoritative and clinically-curated collections of gene variant and disease 
outcomes including 20 genes and 3986 variants allowed the successful extension of 
PSAAP prediction in other gene-disease settings.  This is the largest such collection of 
“diagnostic grade” gene variant phenotype information to date.  As such, this corpus has 
proved valuable when building training and test data sets for machine learning classifiers.  
The generalizability of classification rules across multiple genes and diseases is another 
key contribution of this study. 
4. Combining the PSAAP prediction and other established algorithms with complementary 
approaches allows a standard quantitative metric of gene variant pathogenicity to be 
computed.  This Consensus score was made from scaling each predictor to 100 and 
summing a weighted average based on principle components contribution of each 
predictor.       
5. Where traditional confirming evidence is lacking, a laboratory gene test result may be 
listed as “uncertain significance.”  To avoid this scenario and with analogy to conventional 
laboratory testing, disease reference intervals were calculated using Consensus scores 
of know benign and known pathogenic gene variants.  This reference range of 
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standardized scores from known disease outcomes creates a novel framework for 
evaluation of gene variants of uncertain significance. 
6. Appropriate graphic representation of medical data is vital to communicate disease 
evidence to clinical decision makers.  A proposed visual summary of gathered 
computational evidence was developed for use in laboratory gene test decision making 
and to communicate gene test results to the clinician in a more transparent manner. 
 
Significance 
Personalized medicine implies all relevant information is available on demand to 
clinicians.  Proper interpretation of gene test results is crucial when customizing patient therapy 
[8, 9].  Efforts such as the Human Gene Mutation Database, the Human Variome Project and 
NCBI’s Genetic Testing Registry highlight a growing interest in this important area.   Further, as 
electronic medical records begin to incorporate genome sequencing information, this topic has far 
reaching implications in today’s world of whole genome sequencing and health care reforms. In 
concert, clinicians and diagnostic laboratories are the best source of authoritative gene variant 
annotation. 
Initial efforts to develop clinical laboratory systems included electronic processing and 
reporting of laboratory test results.[10, 11]  Subsequent efforts continued to improve and refine 
computer information systems used in laboratory settings and to enhance patient care.[12, 13]  
As genetic information began to influence patient care, laboratory information systems again 
required adjustments.[14, 15]  Currently, the vast amount of genomic data on the horizon for 
electronic patient records and treatment highlights timely opportunities for genomic data decision 
support in the laboratory setting.  Similar to developing the first clinical laboratory information 
systems, early efforts are beginning to move forward for laboratory decision support in a gene 
testing environment, including combining multiple predictors to improve reliability.[16, 17] 
Of note, where traditional decision support assists in choosing a correct decision or task, 
presenting a rich environment of gene variant information may better support accurate gene test 
interpretation and necessary laboratory recommendations.  Importantly, no pre-conceived filtering 
or formatting of gene variant meta-information should be performed as the various uses of this 
91 
 
data cannot be completely anticipated.  Furthermore, this information should not only reduce the 
overall cognitive load of the test reporting process, but also be made available prior to a clinician 
acting in appropriate patient care.[4, 5, 18] In this light, laboratory decision support tools for 
genomics and sequence variant classification may be the next grand challenge for laboratory 
medicine.   
The initial hypothesis of using machine learning classification to train gene-specific 
algorithms that outperform generalized prediction tools is accepted.  This is due to leveraging 
authoritative gene variant collections, utilizing amino acid physicochemical properties as 
descriptors of wildtype/mutant and Naïve Bayes classification of benign and pathogenic.  
Integrating gene-specific prediction into a decision support framework with quantitative metrics for 
objective evaluation of uncertain gene variants augments laboratory classification of gene test 
results. 
More specifically, laboratory decision support for gene variant classification was improved 
by using primary protein sequence and biochemical properties of amino acid residues as 
descriptors of differences between wild type and variant.  Further, machine learning classification 
was used to predict pathogenicity of uncertain gene variants in authoritative gene-disease 
collections.  Finally, a combined score of complementary predictors was computed in a decision 
support framework of gene-specific disease outcomes. 
 
Limitations 
An important limitation is the fact that despite several ongoing gene variants collections 
such as the 1000 Genomes and the Human Variome Project, a relatively small number of 
clinically-curated and authoritative gene-disease collections exist as used for diagnostic 
purposes.   Fortunately, this number will likely grow over time, as gene-disease associations are 
better understood.  Another limitation is that gene-specific mutation archives often have an 
unbalanced proportion of disease causing gene variants, and appropriate machine learning 
techniques must be used to compensate for uneven training and test data.[19, 20]   
Another key issue is the “moving target” of disease classification of gene variants that 
evolves over time as new knowledge becomes available.  We note that this is a problem whether 
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one uses this proposed framework or the status quo system for dealing with gene test results of 
uncertain significance.  At present, there is no way to communicate new variant knowledge 
effectively between gene test laboratories and clinicians.  Thus, a decision support framework 
should allow for consistent and objective data provenance for longitudinal tracking of both 
variants and patient results, where notifying interested parties in updated variant classification 
and disease association would be more feasible.  We also note that developing this framework 
now, using well-understood monogenic diseases, may allow increased understanding that could 
eventually be applied to multigene panel or whole genome approaches.  Thus, for algorithm 
training and testing to be as straightforward as possible, scenarios of single gene - single disease 
(monogenic) were chosen as a starting point for development of these computational tools.    
Perhaps the most important limitation to acknowledge is how can one know whether a 
prediction for a gene variant of uncertain significance is truly correct?  The honest response is 
likely “you can’t.”   While only the passage of time may confirm the accuracy of a computational 
prediction, an important point not to dismiss is – would this approach (or similar) likely lead to 
better or worse decision making by providers?  There may be analogous situations in other 
existing laboratory tests, where for example, anatomic pathology may yield some ideas that 
clinicians rely on for decision making. The pathology report contains all information, not just the 
“interpretation.” This would imply that more information (not less) is appropriate for clinician 
decision making.[21, 22]   
 
Future efforts 
The challenge of clinical interpretation of genetic sequence remains foremost in 
personalized medicine, regardless if it involves only one gene or an entire genome.  With 
successful efforts to generalize PSAAP and Consensus to other monogenic diseases, the 
extension of these tools into the pending diagnostic setting of multigene panels and next 
generation sequencing becomes even more important.  Future efforts will also be needed to 
augment the PSAAP methodology with an algorithm layer for nucleotide level prediction, 
accounting for “silent” mutational effects not seen in the final translated amino acid product. 
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The use of machine learning algorithms to classify uncertain gene variants in disease is a 
promising decision support tool to enhance gene test interpretation and strengthen our underlying 
knowledge of disease pathogenesis.  Furthermore, improved software algorithms to classify gene 
variants of uncertain significance are necessary to move translational research forward.  This 
novel application of classification algorithms for computational prediction of phenotype severity in 
uncertain gene variants could be generally applied to any gene-disease setting where an 
authoritative corpus of curated gene variants exist and where reported mutations impact clinical 
care.  
Personalized medicine cannot advance until the significance of every laboratory result is 
determined for each patient.  Among the key features critical for a decision support framework in 
clinical genetic testing are first, a reliable scoring metric to predict consequences of a variation 
that alters protein structure and secondly, ease of access to pertinent gene variant information to 
aid the laboratory or clinician when performing clinical diagnoses.  Thus, one crucial future effort 
will be to test the potential of Consensus in regards to improved workflow (laboratory audience) 
as compared to improved interpretation (clinician audience). 
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Summary of Fall 2009, BMI 6950 - Special Topics, Machine Learning with Dr. Scott Narus. 
 
Machine Learning 
9.8.2009 Google search “machine learning” Results 1 - 10 of about 26,600,000. 
9.8.2009 Google Scholar search “machine learning” Results 1 - 10 of about 2,060,000. 
9.8.2009 PubMed search “machine learning” Items 1 - 20 of 35174. (Including 2898 Review articles) 
 
First few original articles were: 
- Singleton WT. An experimental investigation of sewing-machine skill.  Br J Psychol. 1957 
May;48(2):127-32. 
- Hively W.  Programming stimuli in matching to sample.  J Exp Anal Behav. 1962 Jul;5:279-98.  
- Sterling JA, Lowenburg H.  Increased Longevity In Congenital Biliary Atresia.  Ann N Y Acad Sci. 1963 
Dec 30;111:483-508.  
 
Some recent articles were: 
- Re M, Pesole G, Horner DS.  Accurate discrimination of conserved coding and non-coding regions 
through multiple indicators of evolutionary dynamics. BMC Bioinformatics. 2009 Sep 8;10(1):282.  
- Potamitis I, Ganchev T, Kontodimas D. On automatic bioacoustic detection of pests: the cases of 
Rhynchophorus ferrugineus and Sitophilus oryzae. J Econ Entomol. 2009 Aug;102(4):1681-90. 
- Bostan B, Greiner R, Szafron D, Lu P. Predicting Homologous Signaling Pathways Using Machine 
Learning. Bioinformatics. 2009 Sep 7.  
 
Definitions 
Machine learning refers to a system capable of the autonomous acquisition and integration of knowledge. 
This capacity to learn from experience, analytical observation, and other means, results in a system that can 
continuously self-improve and thereby offer increased efficiency and effectiveness. 
 
The ability of a machine to recognize patterns that have occurred repeatedly and improve its performance 
based on past experience. 
 
Ability of a machine to improve its own performance through the use of a software that employs artificial 
intelligence techniques to mimic the ways by which humans seem to learn, such as repetition and 
experience. 
 
A scientific discipline that is concerned with the design and development of algorithms that allow 
computers to learn based on data, such as from sensor data or databases. A major focus of machine learning 
research is to automatically learn to recognize complex patterns and make intelligent decisions based on 
data. It is closely related to fields such as statistics, probability theory, data mining, pattern recognition, 
artificial intelligence, adaptive control, and theoretical computer science. 
 
Extracting useful information from large and complex machine-readable data sets is a problem faced by 
people in nearly every area of commerce, manufacturing, government, and in every academic discipline 
and science. Creating an environment conducive to solving such problems requires assembling a 
community with broad collective expertise in mathematics, statistics, computing, and a wide variety of 
different application areas. 
 
Quotes I liked 
If an expert system--brilliantly designed, engineered and implemented--cannot learn not to repeat its 
mistakes, it is not as intelligent as a worm or a sea anemone or a kitten.  
-Oliver G. Selfridge, from The Gardens of Learning.  
 
Find a bug in a program, and fix it, and the program will work today. Show the program how to find and fix 
a bug, and the program will work forever. 
- Oliver G. Selfridge, in AI's Greatest Trends and Controversies  
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“Exactly what the computer provides is the ability not to be rigid and unthinking but, rather, to behave 
conditionally. That is what it means to apply knowledge to action: It means to let the action taken reflect 
knowledge of the situation, to be sometimes this way, sometimes that, as appropriate. . . . In sum, 
technology can be controlled especially if it is saturated with intelligence to watch over how it goes, to keep 
accounts, to prevent errors, and to provide wisdom to each decision.” 
- Allen Newell, from Fairy Tales 
 
Applications 
Applications for machine learning include machine perception, computer vision, natural language 
processing, syntactic pattern recognition, search engines, medical diagnosis, bioinformatics, brain-machine 
interfaces and cheminformatics, detecting credit card fraud, stock market analysis, classifying DNA 
sequences, speech and handwriting recognition, object recognition in computer vision, game playing, 
software engineering, adaptive websites and robot locomotion. 
 
Algorithms 
Machine learning algorithms are organized into a taxonomy, based on the desired outcome of the 
algorithm. 
 
Common algorithm types include: 
 
Supervised learning - Generates a function that maps inputs to desired outputs. For example, in a 
classification problem, the learner approximates a function mapping a vector into classes by looking at 
input-output examples of the function.  
 
Unsupervised learning - Models a set of inputs: labeled examples are not available.  
 
Semi-supervised learning - Combines both labeled and unlabeled examples to generate an appropriate 
function or classifier.  
 
Reinforcement learning - Learns how to act given an observation of the world. Every action has some 
impact in the environment, and the environment provides feedback in the form of rewards that guides the 
learning algorithm.  
 
Transduction - Tries to predict new outputs based on training inputs, training outputs, and test inputs.  
 
Learning to learn - Learns its own inductive bias based on previous experience. 
 
Supervised learning – Machine learning with some "supervision" in the form of pre-determined 
classifications.  Often involves “training” and “test” sets of data with known labels or outcomes or 
classification which gives feedback about how learning is progressing.  The goal is usually to get the 
computer to learn a classification system that we have created. 
 
Algorithm examples 
Artificial neural network, Backpropagation , Boosting, Bayesian statistics, Case-based reasoning, Decision 
tree learning, Inductive logic programming, Gaussian process regression, Minimum message length 
(decision trees, decision graphs, etc.), Naive bayes classifier, Nearest Neighbor Algorithm, Symbolic 
machine learning algorithms, Subsymbolic machine learning algorithms, Support vector machines, Random 
Forests, Ensembles of Classifiers, Ordinal Classification, Data Pre-processing, Principal Component 
Analysis (PCA). 
 
Unsupervised learning - Models a set of inputs where labeled examples are not available.   The goal is to 







Multivariate analysis, Artificial neural network, Data clustering, Expectation-maximization algorithm, Self-
organizing map, Adaptive resonance theory (ART), Radial basis function network, Generative topographic 
map, Blind Source Separation or Independent Component Analysis (ICA). 
 
Both techniques can be valuable and which one you choose should depend on the circumstances--what kind 
of problem is being solved, how much time is allotted to solving it (supervised learning or clustering is 





In the field of machine learning, semi-supervised learning (SSL) occupies the middle ground, between 
supervised learning (in which all training examples are labeled) and unsupervised learning (in which no 
label data are given).  Olivier Chapelle,  Semi-Supervised Learning (MIT Press, 2006).  
Weakly supervised learning - bootstrapping models from small sets of annotated data.  Indirectly 
supervised learning - end-to-end task evaluation drives learning in an embedded language interpretation 
module. Semi-supervised Learning - uses both labeled and unlabeled data to perform an otherwise 
supervised learning or unsupervised learning task.  http://pages.cs.wisc.edu/~jerryzhu/pub/SSL_EoML.pdf 
 
Academic 
"The Journal of Machine Learning Research (JMLR) provides an international forum for the electronic and 
paper publication of high-quality scholarly articles in all areas of machine learning." 
http://jmlr.csail.mit.edu/ 
MIT Computer Science and Artificial Intelligence Laboratory http://www.csail.mit.edu/ 
Alberta Ingenuity Centre for Machine Learning http://www.machinelearningcentre.ca/ 
Carnegie Mellon University's School of Computer Science, Machine Learning Department  
http://www.ml.cmu.edu/ 
Cornell University’s Department of Computer Science http://www.cs.cornell.edu/ 
University of Cambridge, Computational and Biological Learning Lab http://mlg.eng.cam.ac.uk/ 
UC Irvine Center for Machine Learning and Intelligent Systems http://cml.ics.uci.edu/ 
UC Irvine Machine Learning Repository http://archive.ics.uci.edu/ml/ 
Classification Society of North America (CSNA) http://www.classification-society.org/csna/ 
International Machine Learning Society http://www.machinelearning.org/ 
International Conference on Machine Learning http://www.machinelearning.org/icml.html 
Machine Learning Summer Schools http://mlss.cc/ 
Vertical News http://www.verticalnews.com/search_results.php?search_term=Machine+Learning 
 
Commercial/Industry 
IBM, Microsoft, Yahoo, and Google have substantial efforts in the area of machine learning algorithms. 
IBM - Machine Learning Grouphttp://www.haifa.ibm.com/dept/vst/simulation_vsml_ml.html 
IBM - Mathematical & Computational Sciences http://www.zurich.ibm.com/mcs/ 
 
HAIFA, Israel and ARMONK, N.Y. - 30 Jun 2009: IBM (NYSE: IBM) today announced the public 
availability of Milepost GCC, the world's first open source machine learning compiler. The compiler 
intelligently optimizes applications, translating directly into shorter software development times and bigger 
performance gains. 
 
Machine Learning for Embedded Programs Optimisation http://www.milepost.eu/ 
 
Microsoft Research Cambridge http://research.microsoft.com/en-us/labs/Cambridge/ 
Machine Learning and Applied Statistics (MLAS) http://research.microsoft.com/en-us/groups/mlas/ 
The Machine Learning and Perception group http://research.microsoft.com/en-us/groups/mlp/ 
 
Yahoo! Research http://research.yahoo.com/Machine_Learning 
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The Machine Learning group is a team of experts in computer science, statistics, mathematical 
optimization, and automatic control. We focus on making computers learn abstractions, patterns, 
conditional probability distributions, and policies from web scale data with the goal to improve the online 
experience for Yahoo users, partner publishers, and advertisers. 
 
Military 
Air Force Office of Scientific Research http://www.afisr.af.mil/units/nasic.asp 
Navy Center for Applied Research in Artificial Intelligence http://www.nrl.navy.mil/aic/as/ 
DARPA http://www.darpa.mil/ 
 
Main Funding Sources 
Alberta Ingenuity fund http://www.albertaingenuity.ca/programs/funding/centres/machine/learning 
Alexa http://www.alexa.com/ 










“Machine learning is really good at partially solving just about any problem” (August 20th, 2009 by Partner 
from cdixon.org) 
There’s a saying in artificial intelligence circles that techniques like machine learning (and NLP) can very 
quickly get you, say, 80% of the way to solving just about any (real world) problem, but going beyond 80% 
is extremely hard, maybe even impossible.  The Netflix Challenge is a case in point: hundreds of the best 
researchers in the world worked on the problem for 2 years and the (apparent) winning team got a 10% 
improvement over Netflix’s in-house algorithm.  This is consistent with my own experience, having spent 
many years and dollars on machine learning projects. 
This doesn’t mean machine learning isn’t useful - it just means you need to apply it to contexts that are 
fault tolerant:  for example, online ad targeting, ranking search results, recommendations, and spam 
filtering.  Areas where people aren’t so fault tolerant and machine learning usually disappoints include 
machine translation, speech recognition, and image recognition. 
That’s not to say you can’t use machine learning to attack these non-fault tolorant problems, but just that 
you need to realize the limits of automation and build mechanisms to compensate for those limits.  One 
great thing about most machine learning algorithms is you can infer confidence levels and then, say, ship 
low confidence results to a manual process. 
A corollary of all of the above is that it is very rare for startup companies to ever have a competitive 
advantage because of their machine learning algorithms.  If a worldwide concerted effort can only improve 
Netflix’s algorithm by 10%, how likely are 4 people in an R+D department in a startup going to have a 
significant breakthrough.  Modern ML algorithms are the product of thousands of academics and billions of 
dollars of R+D and are generally only improved upon at the margins by individual companies. 
The NetFlix $1million dollar prize was recently rewarded – with round 2 to begin soon…  
http://www.wired.com/epicenter/2009/09/how-the-netflix-prize-was-won/ 
 
Here at the University of Utah 
Machine Learning Group in CS http://www.cs.utah.edu/~cindi/machine-learning.html 
Cindi Thompson http://www.cs.utah.edu/~cindi/index.html 
(currently with PriceWaterhouse in San Jose) 
Suresh Venkatasubramanian http://www.cs.utah.edu/~suresh/research.html 
Kiri L. Wagstaff AI/ML Scholarship http://www.wkiri.com/projects/klw-scholarship.html 
Hal Daume http://www.cs.utah.edu/~hal/ 




Other software available for machine learning: 
Torch3: a generic machine learning library, particularly good for neural networks, but also a lot more!  
MegaM: Optimization software for maximum entropy models, uses conjugate gradient for 
binary/binomial problems and LM-BFGS for multiclass problems  
FastDT: Very fast decision tree learner that implements bagging and boosting  
libSVM: a very efficient library for SVMs  
SVM-Light: another efficient library for SVMs  
Weka: the "defacto" machine learning/datamining library  









Class for a Naive Bayes classifier using estimator classes. Numeric estimator precision values are chosen 
based on analysis of the training data. For this reason, the classifier is not an UpdateableClassifier (which in 
typical usage are initialized with zero training instances) -- if you need the UpdateableClassifier 
functionality, use the NaiveBayesUpdateable classifier. The NaiveBayesUpdateable classifier will use a 
default precision of 0.1 for numeric attributes when buildClassifier is called with zero training instances. 
 
For more information on Naive Bayes classifiers, see 
 
George H. John, Pat Langley: Estimating Continuous Distributions in Bayesian Classifiers. In: Eleventh 
Conference on Uncertainty in Artificial Intelligence, San Mateo, 338-345, 1995. 
 
OPTIONS 
debug -- If set to true, classifier may output additional info to the console. 
displayModelInOldFormat -- Use old format for model output. The old format is better when there are 
many class values. The new format is better when there are fewer classes and many attributes. 
useKernelEstimator -- Use a kernel estimator for numeric attributes rather than a normal distribution. 
useSupervisedDiscretization -- Use supervised discretization to convert numeric attributes to nominal ones. 
 
CAPABILITIES 
Class -- Binary class, Missing class values, Nominal class 
Attributes -- Numeric attributes, Missing values, Empty nominal attributes, Unary attributes, Binary 
attributes, Nominal attributes 
Additional 
min # of instances: 0 
 
Naïve Bayes (http://weka.sourceforge.net/doc/weka/classifiers/bayes/NaiveBayes.html) 
 
Package weka.classifiers.bayes  
Class Summary 
AODE 
AODE achieves highly accurate classification by averaging over all of a small 
space of alternative naive-Bayes-like models that have weaker (and hence less 
detrimental) independence assumptions than naive Bayes. 
BayesNet Base class for a Bayes Network classifier. 
ComplementNaiveBayes Class for building and using a Complement class Naive Bayes classifier. 
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NaiveBayes Class for a Naive Bayes classifier using estimator classes. 
NaiveBayesMultinomial The core equation for this classifier: P[Ci|D] = (P[D|Ci] x P[Ci]) / P[D] (Bayes rule) where Ci is class i and D is a document 
NaiveBayesSimple Class for building and using a simple Naive Bayes classifier. 







Classifier for building linear logistic regression models. LogitBoost with simple regression functions as 
base learners is used for fitting the logistic models. The optimal number of LogitBoost iterations to perform 
is cross-validated, which leads to automatic attribute selection. For more information see: 
Niels Landwehr, Mark Hall, Eibe Frank (2005). Logistic Model Trees. 
 
Marc Sumner, Eibe Frank, Mark Hall: Speeding up Logistic Model Tree Induction. In: 9th European 
Conference on Principles and Practice of Knowledge Discovery in Databases, 675-683, 2005. 
 
OPTIONS 
debug -- If set to true, classifier may output additional info to the console. 
errorOnProbabilities -- Use error on the probabilties as error measure when determining the best number of 
LogitBoost iterations. If set, the number of LogitBoost iterations is chosen that minimizes the root mean 
squared error (either on the training set or in the cross-validation, depending on useCrossValidation). 
heuristicStop -- If heuristicStop > 0, the heuristic for greedy stopping while cross-validating the number of 
LogitBoost iterations is enabled. This means LogitBoost is stopped if no new error minimum has been 
reached in the last heuristicStop iterations. It is recommended to use this heuristic, it gives a large speed-up 
especially on small datasets. The default value is 50. 
maxBoostingIterations -- Sets the maximum number of iterations for LogitBoost. Default value is 500, for 
very small/large datasets a lower/higher value might be preferable. 
numBoostingIterations -- Set fixed number of iterations for LogitBoost. If >= 0, this sets the number of 
LogitBoost iterations to perform. If < 0, the number is cross-validated or a stopping criterion on the training 
set is used (depending on the value of useCrossValidation). 
useAIC -- The AIC is used to determine when to stop LogitBoost iterations (instead of cross-validation or 
training error). 
useCrossValidation -- Sets whether the number of LogitBoost iterations is to be cross-validated or the 
stopping criterion on the training set should be used. If not set (and no fixed number of iterations was 
given), the number of LogitBoost iterations is used that minimizes the error on the training set 
(misclassification error or error on probabilities depending on errorOnProbabilities). 
weightTrimBeta -- Set the beta value used for weight trimming in LogitBoost. Only instances carrying (1 - 
beta)% of the weight from previous iteration are used in the next iteration. Set to 0 for no weight trimming. 
The default value is 0. 
 
CAPABILITIES 
Class -- Binary class, Missing class values, Nominal class 
Attributes -- Numeric attributes, Missing values, Date attributes, Empty nominal attributes, Unary 
attributes, Binary attributes, Nominal attributes 
Additional 
min # of instances: 1 
 
SimpleLogistic (http://weka.sourceforge.net/doc/weka/classifiers/functions/SimpleLogistic.html) 
Class for building a logistic regression model using LogitBoost. Incorporates attribute selection by fitting 
simple regression functions in LogitBoost. For more information, see master thesis "Logistic Model Trees" 
(Niels Landwehr, 2003). 
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Package weka.classifiers.functions  
Class Summary 
LeastMedSq Implements a least median sqaured linear regression utilising the existing weka LinearRegression class to form predictions. 
LinearRegression Class for using linear regression for prediction. 
Logistic Second implementation for building and using a multinomial logistic regression model with a ridge estimator. 
MultilayerPerceptron A Classifier that uses backpropagation to classify instances. 
PaceRegression Class for building pace regression linear models and using them for prediction. 
RBFNetwork Class that implements a normalized Gaussian radial basis function network. 
SimpleLinearRegression Class for learning a simple linear regression model. 
SimpleLogistic Class for building a logistic regression model using LogitBoost. 
SMO Implements John C. 
SMOreg 
Implements Alex J.Smola and Bernhard Scholkopf sequential minimal 
optimization algorithm for training a support vector regression using 
polynomial or RBF kernels. 
VotedPerceptron Implements the voted perceptron algorithm by Freund and Schapire. 






This class implements a propositional rule learner, Repeated Incremental Pruning to Produce Error 
Reduction (RIPPER), which was proposed by William W. Cohen as an optimized version of IREP.  
 
The algorithm is briefly described as follows:  
 
Initialize RS = {}, and for each class from the less prevalent one to the more frequent one, DO:  
 
1. Building stage: 
Repeat 1.1 and 1.2 until the descrition length (DL) of the ruleset and examples is 64 bits greater than the 
smallest DL met so far, or there are no positive examples, or the error rate >= 50%.  
 
1.1. Grow phase: 
Grow one rule by greedily adding antecedents (or conditions) to the rule until the rule is perfect (i.e. 100% 
accurate).  The procedure tries every possible value of each attribute and selects the condition with highest 
information gain: p(log(p/t)-log(P/T)). 
 
1.2. Prune phase: 
Incrementally prune each rule and allow the pruning of any final sequences of the antecedents;The pruning 
metric is (p-n)/(p+n) -- but it's actually 2p/(p+n) -1, so in this implementation we simply use p/(p+n) 
(actually (p+1)/(p+n+2), thus if p+n is 0, it's 0.5). 
 
2. Optimization stage: 
 after generating the initial ruleset {Ri}, generate and prune two variants of each rule Ri from randomized 
data using procedure 1.1 and 1.2. But one variant is generated from an empty rule while the other is 
generated by greedily adding antecedents to the original rule. Moreover, the pruning metric used here is 
(TP+TN)/(P+N).Then the smallest possible DL for each variant and the original rule is computed.  The 
103 
 
variant with the minimal DL is selected as the final representative of Ri in the ruleset.After all the rules in 
{Ri} have been examined and if there are still residual positives, more rules are generated based on the 
residual positives using Building Stage again.  
3. Delete the rules from the ruleset that would increase the DL of the whole ruleset if it were in it. and add 
resultant ruleset to RS.  
ENDDO 
Note that there seem to be 2 bugs in the original ripper program that would affect the ruleset size and 
accuracy slightly.  This implementation avoids these bugs and thus is a little bit different from Cohen's 
original implementation. Even after fixing the bugs, since the order of classes with the same frequency is 
not defined in ripper, there still seems to be some trivial difference between this implementation and the 
original ripper, especially for audiology data in UCI repository, where there are lots of classes of few 
instances. 
 
Details please see: 
William W. Cohen: Fast Effective Rule Induction. In: Twelfth International Conference on Machine 
Learning, 115-123, 1995. 
 
PS.  We have compared this implementation with the original ripper implementation in aspects of accuracy, 
ruleset size and running time on both artificial data "ab+bcd+defg" and UCI datasets.  In all these aspects it 
seems to be quite comparable to the original ripper implementation.  However, we didn't consider memory 
consumption optimization in this implementation. 
 
OPTIONS 
checkErrorRate -- Whether check for error rate >= 1/2 is included in stopping criterion. 
debug -- Whether debug information is output to the console. 
folds -- Determines the amount of data used for pruning. One fold is used for pruning, the rest for growing 
the rules. 
minNo -- The minimum total weight of the instances in a rule. 
optimizations -- The number of optimization runs. 
seed -- The seed used for randomizing the data. 
usePruning -- Whether pruning is performed. 
 
CAPABILITIES 
Class -- Binary class, Missing class values, Nominal class 
 
Attributes -- Numeric attributes, Missing values, Date attributes, Empty nominal attributes, Unary 
attributes, Binary attributes, Nominal attributes 
Additional 
min # of instances: 3 
 
JRip (http://weka.sourceforge.net/doc/weka/classifiers/rules/JRip.html) 
Xin Xu (xx5@cs.waikato.ac.nz), Eibe Frank (eibe@cs.waikato.ac.nz) 
Package weka.classifiers.rules  
Class Summary 
ConjunctiveRule This class implements a single conjunctive rule learner that can predict for numeric and nominal class labels. 
DecisionTable Class for building and using a simple decision table majority classifier. 
DecisionTable.hashKey Class providing keys to the hash table 
JRip 
This class implements a propositional rule learner, Repeated Incremental 




M5Rules Generates a decision list for regression problems using separate-and-conquer. 
NNge NNge classifier. 
OneR Class for building and using a 1R classifier. 
PART Class for generating a PART decision list. 
Prism Class for building and using a PRISM rule set for classifcation. 
Ridor The implementation of a RIpple-DOwn Rule learner. 
Rule Abstract class of generic rule 
RuleStats 
This class implements the statistics functions used in the propositional rule 
learner, from the simpler ones like count of true/false positive/negatives, filter 
data based on the ruleset, etc. 







Class for building and using a decision stump. Usually used in conjunction with a boosting algorithm. Does 




Eibe Frank (eibe@cs.waikato.ac.nz),  
 
OPTIONS 
debug -- If set to true, classifier may output additional info to the console. 
 
CAPABILITIES 
Class -- Date class, Binary class, Numeric class, Missing class values, Nominal class 
 
Attributes -- Numeric attributes, Missing values, Date attributes, Empty nominal attributes, Unary 
attributes, Binary attributes, Nominal attributes 
 
Additional 
min # of instances: 1 
Package weka.classifiers.trees  
Class Summary 
ADTree Class for generating an alternating decision tree. 
DecisionStump Class for building and using a decision stump. 
Id3 Class implementing an Id3 decision tree classifier. 
J48 Class for generating an unpruned or a pruned C4.5 decision tree. 
LMT Class for "logistic model tree" classifier. 
M5P M5P. 
NBTree Class for generating a Naive Bayes tree (decision tree with Naive Bayes classifiers at the leaves). 
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RandomForest Class for constructing random forests. 
RandomTree Class for constructing a tree that considers K random features at each node. 
REPTree Fast decision tree learner. 
UserClassifier Class for generating an user defined decision tree. 
 
Implements John C. Platt's sequential minimal optimization algorithm for training a support vector 
classifier using polynomial or RBF kernels. This implementation globally replaces all missing values and 
transforms nominal attributes into binary ones. It also normalizes all attributes by default. (Note that the 
coefficients in the output are based on the normalized/standardized data, not the original data.) Multi-class 
problems are solved using pairwise classification. To obtain proper probability estimates, use the option 
that fits logistic regression models to the outputs of the support vector machine. In the multi-class case the 
predicted probabilities will be coupled using Hastie and Tibshirani's pairwise coupling method. Note: for 








K-nearest neighbours classifier. Can select appropriate value of K based on cross-validation. Can also do 
distance weighting. 
 
For more information, see 
 
D. Aha, D. Kibler (1991). Instance-based learning algorithms. Machine Learning. 6:37-66. 
 
OPTIONS 
KNN -- The number of neighbours to use. 
 
crossValidate -- Whether hold-one-out cross-validation will be used to select the best k value. 
 
debug -- If set to true, classifier may output additional info to the console. 
 
distanceWeighting -- Gets the distance weighting method used. 
 
meanSquared -- Whether the mean squared error is used rather than mean absolute error when doing cross-
validation for regression problems. 
 
nearestNeighbourSearchAlgorithm -- The nearest neighbour search algorithm to use (Default: 
weka.core.neighboursearch.LinearNNSearch). 
 
windowSize -- Gets the maximum number of instances allowed in the training pool. The addition of new 
instances above this value will result in old instances being removed. A value of 0 signifies no limit to the 





IB1  IB1-type classifier. 
IBk K-nearest neighbours classifier. 
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KStar K* is an instance-based classifier, that is the class of a test instance is based upon the class of those training instances similar to it, as determined by some similarity function. 
LBR Lazy Bayesian Rules implement a lazy learning approach to lessening the attribute-independence assumption of naive Bayes. 










debug -- If set to true, classifier may output additional info to the console. 
 
CAPABILITIES 
Class -- Date class, Binary class, Numeric class, Missing class values, Nominal class 
 
Attributes -- Numeric attributes, Missing values, Relational attributes, String attributes, Date attributes, 
Empty nominal attributes, Unary attributes, Binary attributes, Nominal attributes 
Additional 
min # of instances: 0 
 
 
Strengths and limitations of common machine learning classifier algorithms. 
 
Weka Classifier  Representative        
Category  Algorithm  Description      
Bayes  Naïve Bayes   Assumes that the conditional probabilities of the 
independent variables are statistically 
independent (class conditional independence). 
However, bias in estimating probabilities often 
may not make a difference in practice.  It is the 
order of the probabilities, not their exact values 
that determine the classifications. Kernel density 
estimation is used for numeric attributes. 
Algorithm Strengths 
Naive Bayes classifiers can handle an arbitrary number of independent variables whether 
continuous or categorical. They have also exhibited high accuracy and speed when applied to 
large databases.  Although relatively simple (mathematically) they are surprisingly effective for 
real-world problems.   
 
Algorithm Limitations 
Often not capable of solving more complex classification problems.  Performance does not 
improve significantly with increasing sample size.  Unrealistic assumption of attribute 
independence. If there are strong attribute dependencies, this algorithm may not perform as well 
as other algorithms designed to handle dependencies. 
 
 
Weka Classifier  Representative        
Category  Algorithm  Description      
Regression SimpleLogistic Builds linear logistic regression models.  
107 
 
LogitBoost with simple regression functions as 
base learners is used for fitting the logistic 
models. The optimal number of iterations to 
perform is cross-validated, which leads to 
automatic attribute selection.   
Algorithm Strengths 
Supports “automatic attribute selection” which places emphasis on variables that appear to 
influence the outcome more than others.   
 
Algorithm Limitations 
Uses a fairly complex approach for arriving at the weights and making the final predictions, so the 
overall model may not be intuitive to the user. 
 
 
Weka Classifier  Representative        
Category  Algorithm  Description  




Rules for classifying instances are easily interpretable, i.e. “transparent” models that enable the 
user to understand exactly how they work.  Rules are typically based on multiple attributes, so 
they explicitly account for dependencies between attributes. 
 
Algorithm Limitations 
Rules may become very complicated and thus be less interpretable and possibly less 
generalizable (called “overfitting”). Pruning can be used to simplify the rules, but often difficult to 
find a balance between pruning enough and pruning too much.  Does not create a condition for a 
keyword which appears in more than two categories – which might lead to contradicting rules. 
 
 
Weka Classifier  Representative        
Category  Algorithm  Description  
Functions                      SMO     A sequential minimal optimization algorithm for  
training a support vector classifier using 
polynomial or RBF kernels. This implementation 
globally replaces all missing values and 
transforms nominal attributes into binary ones. It 
also normalizes all attributes by default, so the 
coefficients in the output are based on the 
normalized/standardized data, not the original 
data.  It uses quadratic programming 
optimization to break complex learning tasks 
down into smaller ones that are easier to solve. 
Algorithm Strengths 
Extremely powerful non-linear classifier (excellent performance in binary classification). 
 
Algorithm Limitations 
Computationally demanding to train and to run.  Sensitive to noisy data.   Prone to overfitting and 




Weka Classifier  Representative        
Category  Algorithm  Description  
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Trees   DecisionStump Builds a classification tree through a process  
known as binary recursive partitioning – basing 
its decision on only one attribute. Missing data is 
treated as a separate value. 
 
Algorithm Strengths 
Fast; simple to implement; can convert result to a set of easily interpretable rules; handles noisy 
data. A good algorithm choice when the data mining task is classification or prediction of 
outcomes and the goal is to generate rules that can be easily understood,.  In cases where a 
single attribute is an excellent predictor, this algorithm performs well because it creates a simple 




"Univariate" splits/partitioning using only one attribute at a time so limits types of possible trees.  




Weka Classifier  Representative        
Category  Algorithm  Description      
Lazy  IBk   K nearest neighbor is a very simple algorithm. It 
is based on the minimum distance from a  
query instance to the training samples and  
determine the K-nearest neighbors. Can also  
do distance weighting. 
Algorithm Strengths 
Can be robust to noisy training data, especially when using inverse square of weighted distance 
as the “distance”.  Remains effective even with large training data sets.  Nonparametric 
architecture, simple and powerful, requires no training time. 
 
Algorithm Limitations 
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